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Summary: Neocortical expansion, thought to underlie the cognitive traits unique to humans, 
is accompanied by cortical folding. This folding starts around gestational week (GW) 20, but 
what causes it remains largely unknown. Extracellular matrix (ECM) has been previously 
implicated in neocortical expansion and here we investigate the potential role of ECM in the 
formation of neocortical folds. We focus on three specific ECM components localized in the 
human fetal cortical plate (CP): hyaluronan and proteoglycan link protein 1 (HAPLN1), 
lumican and collagen I (collectively, HLC). Addition of HLC to cultures of human fetal 
neocortex (11-22 GW) caused local changes in tissue stiffness, induced CP folding, increased 
CP hyaluronic acid (HA) and required the HA-receptor CD168 and downstream ERK 
signaling. Importantly, loss of HA reduced HLC-induced and 22 GW physiological nascent 
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folds. This was altered in samples with neurodevelopmental disorders, indicating it may be a 
useful system to study such disorders. 
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Introduction 
The evolutionary expansion of the neocortex is thought to be a prerequisite for the higher 
cognitive functions that are unique to humans. A key aspect of this expansion is the 
formation of cortical folds, called gyri and sulci, that allow enlargement of the cortical 
surface area within the confinement of the skull (Dehay et al., 2015; Fernandez et al., 2016; 
Florio and Huttner, 2014; Lewitus et al., 2013; Lui et al., 2011; Rakic, 2009; Sun and 
Hevner, 2014; Zilles et al., 2013). Regulation of the number and position of folds is 
fundamental to proper brain function. Both a decrease in folding (e.g. disorders such as 
lissencephaly) as well as an increase in folding (e.g. aberrantly small folds as observed in 
polymicrogyria) are often associated with cognitive defects (Bae et al., 2015; Barkovich et 
al., 2012; Lian and Sheen, 2015; Parrini et al., 2016; Reiner, 1999; Sun and Hevner, 2014). 
 
Despite recent advances in the field that have reported molecular manipulations capable of 
promoting cortical folding (Bae et al., 2014; Borrell, 2018; Florio et al., 2015; Li et al., 2016; 
Masuda et al., 2015; Matsumoto et al., 2017; Shinmyo et al., 2017; Stahl et al., 2013) and 
have modelled mechanical aspects of folding (Bayly et al., 2014; Mota and Herculano-
Houzel, 2015; Tallinen et al., 2016), how defined molecules generate cortical folds in 
mechanistic terms remains largely unknown. Recent studies examining gene expression in 
the developing neocortex (Fietz et al., 2012; Florio et al., 2015; Miller et al., 2014; 
Nowakowski et al., 2017; Pollen et al., 2015; Pollen et al., 2014) identified evolutionary 
changes in gene expression patterns between the embryonic neocortex of mouse, which 
remains smooth (lissencephalic), and the fetal neocortex of human, which folds during 
development (gyrencephalic). Notably, these studies highlighted an increase in the expression 
of extracellular matrix (ECM) components in human germinal zones and cortical progenitor 
cells compared to mouse (Fietz et al., 2012; Florio et al., 2015). This is especially true for the 
outer subventricular zone (OSVZ) (Fietz et al., 2012), the germinal zone of the human 
neocortex that generates the increased numbers of neurons underlying neocortical expansion 
(Dehay et al., 2015; Smart et al., 2002). It has been previously shown that ECM receptors can 
regulate the proliferation of cortical progenitors cells (Fietz et al., 2010; Stenzel et al., 2014). 
Together, these data raise the possibility that ECM may have a role in the expansion of the 
human neocortex. Here we investigate the function of specific ECM components, found to be 
more highly expressed in the human neocortex within these datasets, in human neocortex 
development. 
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Results 
Selection of HAPLN1, lumican and collagen I 
We searched the existing datasets (Albert et al., 2017; Fietz et al., 2012; Florio et al., 2015) 
for specific ECM components (from the core matrisome (Naba et al., 2012)) that are more 
highly expressed in the human than mouse germinal zones and cortical progenitor cell 
populations. To identify ECM components associated with neocortex expansion, we selected 
genes that were expressed by neural progenitor cells (NPCs) in human but not in mouse (see 
Methods for search strategy; Fig 1A). In particular, from these genes more highly expressed 
in human NPCs, we selected those whose expression was down regulated during mouse 
neurogenesis, i.e. that were expressed early in mouse development, during the expansion of 
neuroepithelial cells (E9.5 (Albert et al., 2017)), but were no longer expressed during the 
peak of neurogenesis (E14.5 NPCs (Florio et al., 2015)). This search led to the identification 
of three candidate ECM components: hyaluronan and proteoglycan link protein 1 (HAPLN1), 
the proteoglycan lumican, and the collagen I subunit alpha 2 (see Figure S1A, B for mRNA 
levels (Fietz et al., 2012; Florio et al., 2015), Table 1).  
 
To confirm that these ECM components were expressed at the protein level, 
immunofluorescence (IF) of HAPLN1, lumican and collagen I was performed on 13 GW 
human neocortex and E14.5 mouse neocortex. In the mouse, HAPLN1 and collagen I were 
absent from the neocortex, as expected, but lumican was detected throughout the neocortical 
wall (Figure 1B). Interestingly, in the human tissue, lumican was also found throughout the 
neocortical wall, whereas HAPLN1 and collagen I were more concentrated in the CP than in 
any other region (Figure 1B, S1C), despite the mRNAs for these three ECM components 
being predominantly found in the germinal zones (rather than CP) of human fetal neocortex 
(Fietz et al., 2012) (Figure S1A). Our observations that HLC are more highly concentrated in 
the CP therefore suggest that these ECM components can travel far from their site of origin 
and that progenitor cells may play a role in determining the ECM composition of the 
developing human CP. 
 
HAPLN1, lumican and collagen I induce folding of the CP of 11-14 GW human 
neocortex. 
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ECM components often interact in a network and their function may therefore be greatly 
affected by their environment. As the ECM composition differs between the mouse and 
human (Fietz et al., 2012; Florio et al., 2015), we used two different human fetal neocortex 
explant systems to study the function of HAPLN1, lumican and collagen I in human 
neocortex development and expansion. First, we added recombinant human HAPLN1 and 
lumican (each at 5 µg/ml) to collagen I-embedded organotypic slice cultures of 11-14 GW 
human neocortex. Compared to control (collagen I-embedding only), HAPLN1 and lumican 
addition had a striking effect, inducing folding of the CP after just 24 hours (h) of treatment 
(Figure 2A, S2A). Quantification of this, by adopting the method used to measure the 
gyrencephaly index (GI) in vivo (Zilles et al., 1988), revealed that HAPLN1 and lumican 
addition increased GI from 1.0 (control) to 1.8 (Figure 1B). HAPLN1 appeared to be the 
primary component required, as its addition alone increased GI to 1.5 (Figure 2A, C), 
whereas that of lumican alone did not significantly increase GI (Figure 2C). 
 
In order to characterize the ECM-induced folds, we performed IF for nestin, an intermediate 
filament marker of radial glia progenitors (Dahlstrand, 1995). This revealed three key 
morphological features of the radial glia basal processes; they continued to reach the pial 
surface, followed the curvature of the folds and displayed a fanned appearance (Figure S2A). 
These features are hallmarks of physiological folds, such as those observed in the ferret 
(Reillo et al., 2011). We also performed IF for laminin, which showed that the basal lamina 
invaginated with the folds (Figure 2D), similar to physiological folds observed at later 
developmental stages. 
 
To corroborate these findings in a different explant system, we next examined the effects of 
HAPLN1, lumican and collagen I in free-floating human fetal neocortex tissue culture 
(FFTC). This consists of dissected human fetal neocortex tissue freely floating in medium, 
either without (control) or with the addition of the three ECM components (from now on 
referred to as HLC-treatment). HLC-treatment of FFTCs of 11-14 GW human neocortex 
induced folding of the CP in 24 h (Figure 2B, G), increasing GI to ~1.5 (Figure 2F). The 
lesser increase in GI in comparison to the organotypic slice cultures may reflect the reduced 
penetration of HLC throughout the tissue, due to its greater thickness. However, the 
recombinant proteins used were still able to penetrate the neocortical tissue in this floating 
culture system, as shown by detection of the His-tags of recombinant HAPLN1 and lumican 
throughout the neocortical wall (Fig S1E, F). 
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As observed in organotypic slice cultures, the laminin-stained basal lamina invaginated with 
the folds (Figure 2E), and the nestin-stained radial glia processes reached the pial surface and 
followed the fold curvature, displaying a fanned appearance (Figure 2G). Together these data 
indicate the ECM components HLC can induce folds in 11-14 GW human neocortex explants 
that share key morphological features with folds observed at later developmental stages. 
 
HLC-induced folds form in under 24 h 
We next performed time-lapse imaging of organotypic slice cultures of 12 GW human 
neocortex stained with a vital nuclear dye to observe the formation of the folds over time. 
Control slices (no ECM addition) showed no observable change in CP morphology during 24 
h of culture (Figure 2I top, movie S1), whereas addition of HLC led to the formation of folds 
specifically at the basal (pial) side of the slices between 16 and 24 h (Figure 2I bottom, movie 
S2). 
 
Consistent with the timing observed from the time-lapse imaging, the GI of 12-15 GW 
human neocortex in FFTC was unaltered after 8 h (remaining at ~1.0), slightly increased by 
16 h and significantly increased by 24 h (Figure S2B) upon HLC-treatment. HLC-treatment 
did not cause a further GI increase after 48 and 72 h of culture as compared to 24 h (Figure 
S2C-E). 
 
Folding does not occur with other ECM combinations 
To examine if the specific combination of HLC was required for folding, we tested different 
ECM components and combinations. Collagen I, though insufficient alone (Figure 2C, S2F), 
was required for folding, as addition of only HAPLN1 and lumican did not significantly 
increase GI (Figure 2H). This permissive action was specific to collagen I, as addition of 
HAPLN1, lumican and collagen IV did not induce folding of 14-18 GW human neocortex in 
FFTC (Figure S2G, H). All three HLC components were required for the greatest increase GI 
in FFTC, as neither the individual HLC components alone nor collagen I plus HAPLN1 
(without lumican) were able to increase GI to the level obtained by HLC-treatment in this 
system (Fig S2F). 
 
In contrast to the addition of HAPLN1 and lumican, addition of laminin-211 and collagen IV 
to collagen I-embedded slice cultures did not induce folding of 11-14 GW human neocortex 
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(Figure S2I). Lack of folding of 12-15 GW human neocortex was also observed upon 
addition of a commonly used basement membrane-derived ECM extract to FFTCs (Figure 
S2J). This indicates that it is a specific combination of ECM components, rather than any 
increase in ECM, that can induce such folding of the human CP. 
 
HLC does not induce folding in mouse or ferret neocortex 
In order to investigate if this effect of HLC was conserved across different species, we next 
examined if HLC could induce folding in developing mouse (lissencephalic) and ferret 
neocortex (gryencephalic, GI 1.7 vs. human GI 2.6, (Lewitus et al., 2014)) (Figure S3). 
Several stages were investigated; embryonic day (E) 14.5 mouse and E33 ferret (equivalent 
to 11-14 GW human) neocortex in organotypic slice culture, and E33, postnatal day (P) 9 and 
P15 ferret (physiological folding stages) neocortex in FFTC. Remarkably, addition of HLC 
did not induce folding nor an increase in GI in mouse or ferret neocortex slice cultures after 
24 h (Figure S3A-D), or in ferret FFTCs after 2, 3 or 4 days (Figure S3E-L). As one might 
have expected the ferret as a gyrencephalic animal to be responsive to HLC-treatment, these 
data suggest that the role of HLC in neocortical folding may not be conserved in ferret, or 
that aspects of the pathway required to induce such folding are absent in these species. 
 
IF for HLC reveals differences between ferret and human 
Indeed, IF for HAPLN1, lumican and collagen I in the developing ferret neocortex revealed 
differences between ferret and human. Lumican showed a broad distribution across the 
developing neocortical wall in both species (Figure 1B, S4A-C). However, HAPLN1 and 
collagen I were both absent in E33 ferret neocortex (Figure S4A), but were observed at a low, 
relatively uniform level throughout the cortical wall at P9 and P15 (during fold formation, 
Figure S4B, C). 
 
In comparison, IF for HAPLN1, lumican and collagen I in the human neocortex revealed that 
all three ECM components were detected in the CP at 13 GW (Figure 1B), 18 GW (just prior 
to the onsest of folding, Figure 3A), 22 GW (just after the onset of folding, Figure 3B) and at 
38 GW (when folding is relatively established, Figure 3C). HAPLN1 and lumican were also 
detected throughout the neocortical wall at 18 GW, unlike collagen I (Figure 3A). At the later 
stages (22 and 38 GW) all three components were detected in both the developing gyrus and 
sulcus (Figure 3B, C). At 38 GW, the staining for HAPLN1 has become more diffuse, as seen 
in adult cortex (Uhlen et al., 2015) and lumican and collagen I have become more fibrous. 
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Together, these data suggest that HLC are present in the CP of the human developing 
neocortex both before and during fold formation and the expression of these ECM 
components differs between human and ferret. 
 
HLC-induced folding requires hyaluronic acid 
We next sought to obtain insight into the cellular and molecular mechanisms underlying the 
HLC-induced folding of human fetal neocortex. We first considered increased proliferation 
that would lead to increased neuron production. However, analysis of various markers of 
cycling and mitotic cells showed no significant increase in proliferation (Figure S5). 
Additionally, the use of an inhibitor of cell proliferation (mitomycin C (Hung et al., 1996)) 
alongside HLC-treatment in 11-14 GW human neocortex FFTCs did not significantly reduce 
the GI, indicating that HLC-induced folding does not require progenitor proliferation (Figure 
S5). 
 
Second, comparative transcriptome analysis of 12-14 GW human neocortex after 16 h of 
control and HLC-treatment in FFTC (when HLC-induced folding has just started) revealed 
only minor changes in gene expression, which by gene ontology analysis were found to be 
mostly related to ECM and cell adhesion (Figure S6, Table S1). This suggests that HLC-
induced folding does not involve major changes in gene expression, but only a low level of 
differential gene expression that primarily concerns ECM and cell adhesion. 
 
Finally, we analyzed the level and localization of hyaluronic acid (HA), as HAPLN1 is 
known to interact with and modulate this key ECM component (Binette et al., 1994). 
Immunostaining revealed an increase in the relative level of HA in the CP after 24 h of HLC-
treatment of 11-14 GW human neocortex FFTCs (Figure 4A-B). This increase was already 
observed after 8 and 16 h of HLC-treatment (Figure 4C), suggesting that an increase in HA 
levels in the CP precedes the appearance of HLC-induced folds. This early increase in HA is 
reflected by an increase in the expression of the enzymes that synthesize it, HAS1-3, 6 h after 
HLC-treatment (Fig S6E), along with a reduction in the expression of the enzymes that 
degrade it, HYAL2 and 3 (Fig S6E). These changes in gene expression appeared to be 
transient, as they were no longer detected after 8 h of HLC-treatment (Fig S6E). 
Interestingly, HA was seen to be present throughout the CP at stages of physiological folding 
in the human neocortex, 22 GW and 38 GW (Figure 3C, D), showing a similar diffuse 
staining pattern as HAPLN1 at 38 GW (Figure 3D). 
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In contrast to the human, HLC-treatment of E33 ferret neocortex in FFTC did not 
significantly increase the level of HA in the CP (Figure S3M, N). Moreover, addition of HA 
alongside HLC-treatment did not induce folding of E33 ferret neocortex in FFTC (Figure 
S3O), suggesting that it is not the lack of HA that renders the ferret neocortex non-responsive 
to HLC-treatment. 
 
To determine if HA is required for HLC-induced folding of human fetal neocortex, we added 
a mixture of hyaluronidases (hyals), which degrade HA, together with HLC to 12-14 GW 
human neocortex in FFTC. Addition of hyals to HLC-treatment reduced the level of HA in 
the CP to that of control (Figure 4B, D) and prevented the HLC-induced cortical folding, 
maintaining the GI near 1.0 (Figure 4D, E). Strikingly, hyals were able to reduce HLC-
induced folding when added after 24 h of HLC-treatment, returning the GI back to near 1.0 
(Figure 4E, movie S3) and reducing the level of HA (Fig S7A). Addition of 4-
methylumbelliferone, an inhibitor of HA synthases (HAS) (Rilla et al., 2004), was also able 
to block the HLC-induced cortical folding, suggesting synthesis of HA was required for 
folding to occur (Figure 4F). In contrast to the effect of hyals, addition of chondroitinase 
ABC (chondABC), which targets a glycosaminoglycan component of the ECM distinct from 
HA, did not prevent HLC-induced folding (Figure 4E) or reduce the level of HA (Fig S7A, 
B). Together, these observations indicate that HA exerts a key role in HLC-induced folding 
of early human neocortex. 
 
HLC induces folding in 22 GW human neocortex in FFTC. 
As HLC and HA are expressed in the CP at later stages of human neocortex development 
(Figure 3C, D), this prompted us to investigate whether the HA-dependent HLC-induced 
folding described so far with 11-15 GW human neocortex is of relevance for physiological 
folding, which is known to begin at a later stage of human fetal neocortical development (~20 
GW) (Zilles et al., 2013). To do this we used 22 GW human neocortex in the FFTC system, 
as nascent folds are already present in the CP at this developmental stage, as indicated by an 
increased GI (referred to as inherent GI) of 1.15 in both 22 GW human neocortex not 
subjected to FFTC (Figure 4H) and subjected to control treatment in FFTC (Figure 4G-K). 
We next subjected 22 GW human neocortex in FFTC to HLC-treatment for 4 days and found 
that this significantly increased GI above the inherent value (from 1.15 to ~1.3; Figure 4G, I, 
J). At this developmental stage, no GI increase by HLC was observed after only 24 h of 
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treatment (Figure S7D). This could be due to increased thickness of the 22 GW tissue and 
CP, as more time would be needed for HLC to penetrate the CP and initiate folding. 
 
The thickness of the CP could also help to explain why the HLC-induced folds observed at 
22 GW were larger than those observed at earlier stages. The thickness of the CP has been 
previously hypothesized to influence the number and size of cortical folds (Bayly et al., 2014; 
Richman et al., 1975), where the intergyral distance is thought to be related to the thickness 
of the cortical plate. In line with this theory, the folds present in the 11-16 GW tissue have a 
relatively smaller intergyral distance than the inherent physiological folds observed in the 22 
GW tissue (Figure S7E), whereas the folds in 22 GW tissue treated with HLC are more 
similar to the inherent folds present at 22 GW (Figure S7E). These data suggest that HLC-
treatment induces a level of folding that is related to the thickness of the CP, resulting in a 
smaller intergyral distance in 11-16 GW samples than 22 GW samples. 
 
Loss of HA reduces the inherent folding present in 22 GW human neocortex in FFTC 
As addition of HLC was able to increase the level of folding in 22 GW neocortex, we next 
examined if this required HA, as in the earlier stages of neocortex examined. As HA is 
known to generally turn over relatively quickly (Fraser et al., 1997), we used a HAS inhibitor 
(Figure S7C, F) and hyals to remove HA in this later stage tissue. This combination blocked 
the HLC-induced increase in GI observed after 4 days of FFTC (Figure 4G) but, more 
strikingly, also reduced the inherent GI to ~1.0 (Figure 4G, H). This reduction of inherent GI 
to ~1.0 was also observed when either the HAS inhibitor, hyals or a combination of both 
were added to 22 GW neocortex in FFTC for 4 days (without HLC) (Figure 4H, I K) or for 
24 h (Figure S7G). Overall, these data suggest that HA is important to maintain the nascent 
physiological folds present in 22 GW neocortex. 
 
This was not the case for the early stages of folding in the ferret neocortex. Treatment of P15 
ferret neocortex with hyals and HAS inhibitor for 2 days in FFTC did not reduce its inherent 
GI (1.2-1.3, Figure S3P, Q) as we observed in the human neocortex. This is consistent with 
the inability of HLC-treatment to raise HA levels in the CP (Figure S3M, N), or of HA 
supplementation to HLC-treatment to increase GI of E33 ferret neocortex (Figure S3O). 
 
HLC-induced folding replicates aspects of physiological nascent folds at 22 GW 
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Our data indicate that HLC-induced folding and physiological nascent folds both required 
HA in the CP, suggesting a shared feature between the two mechanisms. To examine if there 
were other similarities between HLC-induced and nascent physiological folds, we next 
investigated the degree of folding in the CP layers. Physiological folding initially occurs 
more so in the upper most CP layers, with the deeper layers becoming more folded over the 
course of development. In keeping with this, the nascent physiological folds present at 22 
GW show increased folding the upper neuronal layers in comparison to the deeper layers, as 
observed by IF for TBR1 and CTIP2, two markers of deep-layer neurons with distinct 
expression patterns in layers VI and V respectively (Molyneaux et al., 2007) (Figure 5A). 
HLC-induced folding of 15 GW human neocortex replicated this, as the CTIP2 positive 
neuronal layer was more folded than the TBR1 layer below it (Figure 5B), closely resembling 
the nascent physiological folds present at 22 GW. 
 
During the formation of these nascent folds and rearrangement of neuronal layers, the CP 
undergoes large morphological changes that could lead to differential spacing of cells within 
the developing gyrus verses the sulcus. Indeed, when we examined the nuclei within the 
nascent gyrus of non-cultured 22 GW neocortex, we observed a greater distance between 
them than in comparison to the developing sulcus (Figure S7H, I). This aspect of 
physiological nascent folds was also observed in the HLC-induced folds of 11-14 GW 
neocortex in FFTC (Figure 5C-E). This increase in nuclei distance could already be observed 
at 8 h (slight shift right in frequency distribution, Figure S7J, K) and was overt by 16 h 
(Figure S7L, M), indicating that the distance between nuclei increased as HLC-induced 
folding proceeded. Taken together, these data indicate that HLC-induced folds replicate 
specific aspects of the physiological nascent folds observed at 22 GW. 
 
HLC induce a specific pattern of ECM stiffness that is present in physiological nascent 
folds 
To further investigate the mechanism underlying HLC-induced folding, we next examined 
ECM stiffness within the CP. There were two reasons for this, first that ECM stiffness has 
been linked to changes in cell migration and spacing (Miron-Mendoza et al., 2010), and 
second that the HLC components have been previously shown to modify ECM organization 
(Binette et al., 1994; Schaefer and Iozzo, 2008). Changes in ECM organization, such as the 
increase in HA in the CP after HLC-induced folding (Figure 4A, B), can lead to changes in 
ECM stiffness, suggesting that this may be altered in HLC-induced folding. 
Long et al,   30 May 2018 
 
 12 
 
To explore this, we performed atomic force microscopy (AFM) with 12-14 GW human 
neocortex tissue that following FFTC had undergone freeze-thawing (Figure S8A, B), an 
established approach to examine the ECM within various tissues irrespective of cell viability 
(Graham et al., 2010). AFM revealed that the CP gyri formed upon HLC-treatment were 
stiffer than the neighboring sulci, the stiffness of which was comparable to control CP 
(Figure 5F-H). This pattern of alterations in ECM stiffness was already detectable after 8 h of 
HLC-treatment, prior to fold formation (Figure S8C). It was then overt after 16 h of HLC-
treatment, when HLC-induced folding has just started (Figure 5G, S8D). Importantly, 
increased ECM stiffness in nascent gyri compared to sulci in non-cultured 22 GW neocortex 
was also observed by AFM (Figure 5I), suggesting that this is a physiological characteristic 
of nascent folds. 
 
The observed increase in ECM stiffness in nascent gyri compared to sulci (Figure 5I) and the 
HA-dependence of the inherent GI (Figure 4H, I, K) of 22 GW human neocortex raised the 
possibility of a causal relationship between HA levels and the ability of the ECM to undergo 
alterations in stiffness. Indeed, treatment of 22 GW human neocortex in FFTC for 4 days 
with hyals and HAS inhibitor reduced the range of stiffness values to half of control, as 
determined by AFM (Figure 5J). Furthermore, in line with the notion that increases in ECM 
stiffness underlie the formation of gyri vs. sulci upon HLC-treatment, as observed with 12-14 
GW human neocortex (Figure 5F-H, Figure S8C, D), HLC-treatment of 22 GW human 
neocortex in FFTC for 4 days dramatically increased the range of stiffness values compared 
to control (Figure 5J). 
 
Interestingly, although HLC-treatment of E33 ferret neocortex in FFTC was unable to induce 
folding in the developing ferret neocortex, we did observe that HLC-treatment was able to 
cause local increases in ECM stiffness in the CP (Figure S3R, S). This suggests that HLC can 
induce some changes in the ferret neocortex, but that it cannot induce folding. This may be 
due to a lack of other downstream components in the ferret neocortex, or that these 
components are not activated by such changes in ECM stiffness. 
 
HA receptor CD168 and downstream ERK signaling are required for HLC-induced 
folding 
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We next further investigated the mechanism behind the HA-dependent, HLC-induced folds in 
the human CP. To obtain mechanistic insight into the HA-dependency we examined the 
expression of the two major HA-receptors, CD44 and CD168 (also called Receptor for HA-
Mediated Motility (RHAMM)) (Casini et al., 2010; Dzwonek and Wilczynski, 2015; Lynn et 
al., 2001; Nagy et al., 1995). IF of 13 and 22 GW human neocortex showed that CD44 was 
uniformly distributed in the CP at both developmental stages (Figure 6A, B). However, 
although CD168 was distributed throughout the CP at 13 GW (Figure 6A), it was more 
highly expressed in nascent gyri than sulci at 22 GW (Figure 6B). 
 
These data raised the possibility that activation of CD168 or CD44 may be required for HLC-
induced folding of the human CP. We therefore performed HLC-treatment of 12-15 GW 
human neocortex in FFTC in the presence of a CD168 antibody and a CD44 antibody. The 
CD168 antibody essentially blocked the HLC-induced folding, maintaining the GI at 1.0 
(Figure 6C, D), whereas the CD44 antibody did not significantly reduce the HLC-induced GI 
increase (Figure 6C, D). Interestingly, the CD168 antibody also blocked the increase in HA 
in the CP observed after HLC-treatment, unlike the CD44 antibody (Figure 6E). This 
indicates that the HA-receptor CD168, rather than CD44, is required for the HA-dependent, 
HLC-induced folding of the human CP. 
 
CD168 and CD44 have been shown to regulate neuron migration via the ERK pathway (Lynn 
et al., 2001; Zhang et al., 1998). We therefore next performed IF for phospho-ERK (pERK), 
a marker of active ERK signaling, on 12-15 GW human neocortex in FFTC. We observed 
that HLC-treatment activated ERK signaling, increasing the pERK level to 1.5 times that of 
control (Figure 6F). This increase was already observed after 8 h of HLC-treatment (Figure 
6G), suggesting it precedes the appearance of HLC-induced cortical folding, and was equally 
increased in gyri compared to their neighboring sulci after 24 h of HLC-treatment (Fig 6H). 
This activation of ERK by HLC-treatment was not significantly lowered by the CD44 
antibody (Figure 6F), but was significantly reduced by the CD168 antibody, which reduced 
pERK levels below that of control (Figure 6F). Of note, the degradation of hyaluronic acid by 
addition of hyals prevented the HLC-induced increase in pERK levels, maintaining them at 
the level of the control (Fig 6I). 
 
This indicated that ERK activation by HLC-treatment is downstream of the HA receptor 
CD168. To examine if ERK signaling was required for HLC-induced folding, we next added 
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an inhibitor of ERK1/2 in addition of HLC-treatment. This ERK1/2 inhibitor, which reduced 
the levels of the ERK downstream target p90RSK in the CP (Fig S7N, O), blocked the HLC-
induced increase in GI in 12-16 GW human neocortex in FFTC (Figure 6J, K), maintaining 
the GI at 1.0. Together, these data suggest that HLC-induced folding of the human CP 
requires the activation of ERK signaling downstream of the HA-receptor CD168. 
 
ECM stiffness requires HA and is upstream of CD168/ERK signaling 
As HLC-induced folds increased ECM stiffness and require CD168/ERK signaling, we next 
investigated the connection between these two features. To do so, we used AFM to examine 
how ECM stiffness was affected by the addition of the CD168 antibody, ERK inhibitor, 
chondABC or hyals to HLC-treatment in 13-15 GW human neocortex in FFTC for 24 h. The 
addition of either the CD168 antibody or ERK inhibitor was sufficient to block the HLC-
induced increase in GI (Fig 6D, J), but did not reduce the increased ECM stiffness values 
measured by AFM after HLC-treatment (Fig S8E). In contrast, the addition of hyals was 
sufficient to block both the HLC-induced increase in GI (Fig 4E) and the increased ECM 
stiffness (Fig S8E). This reduction in ECM stiffness was not due to a general disruption of 
the ECM, as addition of chondABC, which did not block the HLC-induced increase in GI, 
did not reduce the HLC-induced increase in ECM stiffness either (Fig S8E). This indicates 
that HA is required for the HLC-induced increase in ECM stiffness, and that this HA-linked 
increased stiffness is upstream of CD168/ERK signaling. Taken together, these data suggest 
that both the HA-linked ECM stiffness and the downstream CD168/ERK signaling are 
required for HLC-induced folding. 
 
HLC-induced folding as an assay to examine neurodevelopmental disorders (NDDs) 
Our observations that HLC-treatment increased the GI not only of 11-14 GW (Figure 2) but 
also of 22 GW (Figure 4G, I, J) human neocortex in an HA-dependent manner, and was able 
to replicate aspects of physiological nascent folds, suggest that this system may be a useful 
model to study aspects of physiological folding in the human CP. In particular, HLC-induced 
folding could have potential as an assay in which to study various human NDDs. We 
therefore examined human neocortex samples from fetuses with altered neocortex 
development, notably five cases of Down syndrome (DS) (trisomy 21). Remarkably, in 
contrast to 11-15 GW non-trisomy human neocortex (Figure 2), HLC-treatment of 14-17 GW 
DS neocortex in FFTC did not induce folding (Figure 7A-C). However, when a later 
developmental stage of DS (21 GW) was examined, HLC-treatment was able to significantly 
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increase GI above the inherent value (from ~1.1 to ~1.2) of this neocortex tissue in a HA-
dependent manner (Figure 7F, G), as was the case for 22 GW non-trisomy human neocortex 
(Figure 4G, I, J). 
 
Analysis of two other fetal samples with altered neocortex development, prenatal 
methamphetamine exposure (PME) (12 GW) and 2p16.3 microdeletion (16 GW) was also 
performed. These two developmental disorders are interesting as PME has been previously 
reported to affect cortical folding in animal models (Jablonski et al., 2016), whereas in 
contrast, 2p16.3 microdeletions are not known to affect these aspects of cortical 
development, but rather affect synaptic activity and susceptibility to psychiatric disorders 
(Vinas-Jornet et al., 2014). Accordingly, HLC-treatment in FFTC did not induce folding in 
the PME sample, but was able to significantly increase the GI in the 2p16.3 microdeletion 
sample (Figure 7B, D, E). 
 
Consistent with these data, the relative level of HA in the CP was only increased in the 
2p16.3 microdeletion sample (small increase) and the 21 GW DS sample (three-fold 
increase) after HLC-treatment when compared to control, whereas no relative increase in HA 
was observed in the PME sample or the 14 GW Downs sample (Figure 7H, I). Taken 
together, these data suggest HLC-induced folding revealed known aspects of various NDDs 
including abnormal folding after PME and normal folding in a 2p16.3 microdeletion sample. 
It also revealed aspects of disorders that are not yet fully understood, such as the delayed 
response of DS tissue to HLC-induced folding which may reflect the developmental delay or 
slight reduction in sulcal depth seen in some DS cases (Annus et al., 2017). Together, these 
data suggest that HLC-induced folding has potential as an assay in which to further study 
such NDDs. 
 
Discussion 
In conclusion, our study presents three major findings. Firstly, we have established an in vitro 
model of fetal human neocortical folding that can be used for the mechanistic dissection of 
fold formation and to investigate the NDDs associated with abnormal neocortical folding. 
Secondly, we have established a key role of the specific ECM components HAPLN1, 
lumican and collagen I in the formation of cortical folds in the fetal human neocortex. 
Thirdly, we have established that local changes in tissue stiffness, rearrangement of HA and 
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the HA receptor CD168 play key roles in the regulation of early folding in the human 
neocortex. 
 
There are currently several concepts as to how neocortical folds are formed, ranging from 
mechanical to genetic (Borrell, 2018; Kroenke and Bayly, 2018). Genetic studies have 
identified areas in the developing ferret neocortex that are predetermined to fold (De Juan 
Romero et al., 2015) and have shown that individual genes can induce folding in mice (Florio 
et al., 2015; Stahl et al., 2013). Of note from the mechanical models, it has been proposed 
that folding occurs due to the non-uniform tangential basal expansion observed in neocortical 
development (Tallinen et al., 2014; Tallinen et al., 2016). Folding of the human neocortex is 
most likely regulated by a combination of these genetic and mechanical factors, which will 
interact and modulate each other. Here, our data suggest the ECM as an interesting candidate 
to link these two models, as manipulation of the ECM can induce and alter the initial stages 
of folding, in part by modifying ECM stiffness. This suggests that transcriptional regulation 
of ECM expression, and the factors that modulate it, could be important for the regulation of 
physiological folding in human neocortex development. 
 
Although HLC-induced folding replicated specific aspects of physiological nascent folds, 
several aspects are clearly different. For example, HLC-induced folding did not require the 
proliferation of progenitors to induce folding and it occurred prematurely, in fetal tissue 
obtained weeks prior to when folding starts in vivo (~20 GW) and at a much faster rate. 
Normally folding occurs over the course of weeks, not within a few hours as with HLC-
induced folding, allowing increased neuron production over time to play a key role in fold 
formation. In support of this, genes differentially expressed in areas predetermined to form 
gyri versus sulci are known to increase neuron production (De Juan Romero et al., 2015).  
However, when 22 GW human fetal neocortex was treated with HLC, folds did not form in 
24 h, but instead in 4 days.  This would be more in-keeping with the physiological timeline of 
cortical folding and suggests that the younger tissue folds faster due to its smaller size, i.e. a 
thinner CP. In physiological development, the endogenous HLC and HA present in the 20 
GW human neocortex may promote folding over a more prolonged time frame.  This is faster 
in our in vitro system due to the increase in HLC levels, after the addition of the recombinant 
proteins, which could result in a faster rearrangement of the ECM environment and increased 
CD168 signaling. 
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Instead of replicating aspects of physiological folding such as proliferation, HLC-induced 
folding may instead highlight additional factors required for fold formation in vivo; the 
mechanics and signaling of the ECM. Addition of HLC to the human neocortex led to 
increased HA within the CP. This could create an environment permissive to fold formation, 
as HA is known to facilitate both the migration of cells and tissue morphogenesis via the 
RHAMM/CD168 receptor and loosening of the cell-ECM environment (Margolis et al., 
1975; Solis et al., 2012). This possible function of HA in the CP is in line with a recent 
finding that reducing intracellular adhesion between the newborn neurons in the 
lissencephalic mouse caused the formation of sulci in the CP (Del Toro et al, 2017). The 
increase of HA in the CP and triggering of the CD168-ERK1/2 pathway, downstream of the 
increase in local ECM stiffness detected by AFM, could cause the movement of cells away 
from the areas with lowest stiffness towards the neighboring, stiffer areas (as observed in 
other systems (Kim et al., 2018; Lange and Fabry, 2013)), where the formation of expanding 
gyri can be supported by the stiffer ECM environment. This expansion could be further 
supported by the increase in HA, as loss of HA from early embryos has been previously 
reported to reduce their size (Morriss-Kay et al., 1986). Further support for this comes from 
the reduction of inherent folds at 22 GW caused by the loss of HA, suggesting maintenance 
of HA is required in this initial stage of neocortex folding. This combination of HA, ECM 
stiffness and downstream CD168/ERK signaling could therefore enable the neocortex to self-
organize and modulate the environment to be either permissive to folding or not, ensuring 
that the folds form in the correct place (a process tightly regulated in physiological 
development). The HLC-induced folding system we have shown could be a useful tool in 
which to study how the location and formation of folds is regulated, including if there are any 
feedback loops between various parts of the HA/stiffness/CD168/ERK pathway. In this 
context, it would be interesting to develop approaches to manipulate ECM stiffness in a HA-
independent manner to examine if such increases in stiffness are still required for folding, or 
if a HA increase and signaling via CD168/ERK are sufficient to induce folding. 
 
This fold-inducing function of HLC and HA does not appear to be a common mechanism 
among all gyrencephalic species, as HLC treatment did not cause folding in the ferret at any 
age examined.  However, as it was able to induce some changes in ECM stiffness, as 
measured by AFM, we cannot exclude the possibility that some of the steps in the complex 
process leading to HLC-induced folding are also initiated in the ferret, but fail to result in 
folding due to the lack of other downstream factors. Although we observed a lack of 
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HAPLN1 staining in the E33 ferret neocortex, HAPLN1 was detected at both P9 and P15, 
suggesting the absence of HAPLN1 was not responsible for the lack of folding.  It is also 
unlikely that this is due to differences in the sequence homology of the ferret HAPLN1 
protein compared to human HAPLN1, as it retains a 100% homology of the two link 
domains, which are able to bind HA.  However, we also observed HA is not required for 
folding in the ferret neocortex as it is in human; addition of hyals and a HAS inhibitor were 
unable to reduce the GI of P9 or P15 ferret neocortex in FSN cultures, in contrast to 22 GW 
human neocortex FSN cultures.  This lack of requirement of HA is also reflected in the 
location of the HA receptor CD168, which was observed at a lower level and in a more 
uniform pattern in the ferret CP at these later stages (P9, P15; Figure S6D, E) compared to a 
higher level around the newly forming gyrus in 22 GW human neocortex (Figure 6B).  
Overall, these data suggest that HLC and HA do not play the same role in folding of the 
ferret neocortex, but it could be possible that other ECM components may be have a similar 
role in folding in this system instead. 
 
 
Taken together, these data suggest HLC-induced folding could provide a useful system in 
which to study various aspects of human NDDs. This is especially prevalent for those 
disorders that lack model systems that accurately replicate specific aspects of the disorder, for 
example abnormalities of neocortex folding observed in lissencephalies and polymicrogyria. 
While this manuscript was in preparation, a study was published investigating the physics of 
neuroepithelial organoid folding in organoids from WT and Lis 1 mutant cells (Karzbrun et 
al., 2018). Interestingly, these Lis 1 mutant organoids showed a reduction in folding within 
this system and a reduction in Col1a2 levels, suggesting a potential physiological role of 
Col1a2 in such folding disorders. Here we show that HLC-induced folding revealed known 
aspects of various other NDDs, including abnormal folding after PME but not 2p16.3 
microdeletion. It also revealed a delay in response to HLC-treatment in DS neocortex. DS is 
known to be associated with delayed development of the CP at early stages, which then 
catches up later in development (Golden and Hyman, 1994; Haydar and Reeves, 2012). Our 
present observations could therefore provide a useful system in which to study the early 
developmental delays seen in DS, allowing the examination of differential responses of 
neurons within the CP of DS and non-affected neocortex tissue. 
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Overall, our study has identified that the ECM components HAPLN1, lumican, collagen I 
and HA, their modulation of local tissue stiffness and the HA receptor CD168 as additional 
key players in the induction of fold formation in the human neocortex. It may also provide a 
link between the genetic and mechanical models, as regulation of the ECM by altering 
expression of the components themselves or the enzymes that can modify them, can allow the 
cells to regulate their own mechanical environment. Although our HLC-induced folding may 
not recapitulate every aspect of physiological folding, it has allowed us to uncover, and 
prematurely activate, a novel ECM-driven mechanism that can regulate early aspects of 
human neocortical folding and could be used to provide further insight into human 
neocortical development and its associated disorders. 
 
 
  
Long et al,   30 May 2018 
 
 20 
References and Notes 
Albert, M., Kalebic, N., Florio, M., Lakshmanaperumal, N., Haffner, C., Brandl, H., Henry, I., 
and Huttner, W.B. (2017). Epigenome profiling and editing of neocortical progenitor cells 
during development. The EMBO journal 36, 2642-2658. 
Annus, T., Wilson, L.R., Acosta-Cabronero, J., Cardenas-Blanco, A., Hong, Y.T., Fryer, T.D., 
Coles, J.P., Menon, D.K., Zaman, S.H., Holland, A.J., et al. (2017). The Down syndrome brain 
in the presence and absence of fibrillar beta-amyloidosis. Neurobiol Aging 53, 11-19. 
Bae, B.I., Jayaraman, D., and Walsh, C.A. (2015). Genetic changes shaping the human brain. 
Dev Cell 32, 423-434. 
Bae, B.I., Tietjen, I., Atabay, K.D., Evrony, G.D., Johnson, M.B., Asare, E., Wang, P.P., 
Murayama, A.Y., Im, K., Lisgo, S.N., et al. (2014). Evolutionarily dynamic alternative splicing 
of GPR56 regulates regional cerebral cortical patterning. Science 343, 764-768. 
Barkovich, A.J., Guerrini, R., Kuzniecky, R.I., Jackson, G.D., and Dobyns, W.B. (2012). A 
developmental and genetic classification for malformations of cortical development: update 
2012. Brain 135, 1348-1369. 
Bayly, P.V., Taber, L.A., and Kroenke, C.D. (2014). Mechanical forces in cerebral cortical 
folding: a review of measurements and models. J Mech Behav Biomed Mater 29, 568-581. 
Binette, F., Cravens, J., Kahoussi, B., Haudenschild, D.R., and Goetinck, P.F. (1994). Link 
protein is ubiquitously expressed in non-cartilaginous tissues where it enhances and stabilizes 
the interaction of proteoglycans with hyaluronic acid. J Biol Chem 269, 19116-19122. 
Borrell, V. (2018). How Cells Fold the Cerebral Cortex. J Neurosci 38, 776-783. 
Casini, P., Nardi, I., and Ori, M. (2010). RHAMM mRNA expression in proliferating and 
migrating cells of the developing central nervous system. Gene Expr Patterns 10, 93-97. 
Dahlstrand, J., Lardelli, M. & Lendahl, U. (1995). Nestin mRNA expression correlates with 
the central nervous system progenitor cell state in many, but not all, regions of developing 
central nervous system. Dev Brain Res 84, 109-129. 
De Juan Romero, C., Bruder, C., Tomasello, U., Sanz-Anquela, J.M., and Borrell, V. (2015). 
Discrete domains of gene expression in germinal layers distinguish the development of 
gyrencephaly. The EMBO journal 34, 1859-1874. 
Dehay, C., Kennedy, H., and Kosik, K.S. (2015). The outer subventricular zone and primate-
specific cortical complexification. Neuron 85, 683-694. 
Dzwonek, J., and Wilczynski, G.M. (2015). CD44: molecular interactions, signaling and 
functions in the nervous system. Front Cell Neurosci 9, 175. 
Fernandez, V., Llinares-Benadero, C., and Borrell, V. (2016). Cerebral cortex expansion and 
folding: what have we learned? The EMBO journal 35, 1021-1044. 
Fietz, S.A., Kelava, I., Vogt, J., Wilsch-Brauninger, M., Stenzel, D., Fish, J.L., Corbeil, D., 
Riehn, A., Distler, W., Nitsch, R., et al. (2010). OSVZ progenitors of human and ferret 
Long et al,   30 May 2018 
 
 21 
neocortex are epithelial-like and expand by integrin signaling. Nature neuroscience 13, 690-
699. 
Fietz, S.A., Lachmann, R., Brandl, H., Kircher, M., Samusik, N., Schroder, R., 
Lakshmanaperumal, N., Henry, I., Vogt, J., Riehn, A., et al. (2012). Transcriptomes of 
germinal zones of human and mouse fetal neocortex suggest a role of extracellular matrix in 
progenitor self-renewal. Proceedings of the National Academy of Sciences of the United States 
of America 109, 11836-11841. 
Florio, M., Albert, M., Taverna, E., Namba, T., Brandl, H., Lewitus, E., Haffner, C., Sykes, 
A., Wong, F.K., Peters, J., et al. (2015). Human-specific gene ARHGAP11B promotes basal 
progenitor amplification and neocortex expansion. Science 347, 1465-1470. 
Florio, M., and Huttner, W.B. (2014). Neural progenitors, neurogenesis and the evolution of 
the neocortex. Development 141, 2182-2194. 
Fraser, J.R., Laurent, T.C., and Laurent, U.B. (1997). Hyaluronan: its nature, distribution, 
functions and turnover. J Intern Med 242, 27-33. 
Golden, J.A., and Hyman, B.T. (1994). Development of the superior temporal neocortex is 
anomalous in trisomy 21. J Neuropathol Exp Neurol 53, 513-520. 
Graham, H.K., Hodson, N.W., Hoyland, J.A., Millward-Sadler, S.J., Garrod, D., Scothern, A., 
Griffiths, C.E., Watson, R.E., Cox, T.R., Erler, J.T., et al. (2010). Tissue section AFM: In situ 
ultrastructural imaging of native biomolecules. Matrix Biol 29, 254-260. 
Haydar, T.F., and Reeves, R.H. (2012). Trisomy 21 and early brain development. Trends 
Neurosci 35, 81-91. 
Hoogendoorn, R.J., Wuisman, P.I., Smit, T.H., Everts, V.E., and Helder, M.N. (2007). 
Experimental intervertebral disc degeneration induced by chondroitinase ABC in the goat. 
Spine (Phila Pa 1976) 32, 1816-1825. 
Hung, D.T., Jamison, T.F., and Schreiber, S.L. (1996). Understanding and controlling the cell 
cycle with natural products. Chem Biol 3, 623-639. 
Hutter, J.L., and Bechhoefer, J. (1993). Calibration of Atomic-Force Microscope Tips (Vol 64, 
Pg 1868, 1993). Rev Sci Instrum 64, 3342-3342. 
Jablonski, S.A., Williams, M.T., and Vorhees, C.V. (2016). Mechanisms involved in the 
neurotoxic and cognitive effects of developmental methamphetamine exposure. Birth Defects 
Res C Embryo Today 108, 131-141. 
Karzbrun, E., Kshirsagar, A., Cohen, S.R., Hanna, J.H., and Reiner, O. (2018). Human Brain 
Organoids on a Chip Reveal the Physics of Folding. Nat Phys 14, 515-522. 
Kim, M.C., Silberberg, Y.R., Abeyaratne, R., Kamm, R.D., and Asada, H.H. (2018). 
Computational modeling of three-dimensional ECM-rigidity sensing to guide directed cell 
migration. Proc Natl Acad Sci U S A 115, E390-E399. 
Long et al,   30 May 2018 
 
 22 
Krieg, M., Arboleda-Estudillo, Y., Puech, P.H., Kafer, J., Graner, F., Muller, D.J., and 
Heisenberg, C.P. (2008). Tensile forces govern germ-layer organization in zebrafish. Nat Cell 
Biol 10, 429-436. 
Kroenke, C.D., and Bayly, P.V. (2018). How Forces Fold the Cerebral Cortex. J Neurosci 38, 
767-775. 
Lange, J.R., and Fabry, B. (2013). Cell and tissue mechanics in cell migration. Exp Cell Res 
319, 2418-2423. 
Lewitus, E., Kelava, I., and Huttner, W.B. (2013). Conical expansion of the outer 
subventricular zone and the role of neocortical folding in evolution and development. Front 
Hum Neurosci 7, 424. 
Lewitus, E., Kelava, I., Kalinka, A.T., Tomancak, P., and Huttner, W.B. (2014). An adaptive 
threshold in mammalian neocortical evolution. PLoS Biol 12, e1002000. 
Li, Y., Muffat, J., Omer, A., Bosch, I., Lancaster, M.A., Sur, M., Gehrke, L., Knoblich, J.A., 
and Jaenisch, R. (2016). Induction of Expansion and Folding in Human Cerebral Organoids. 
Cell Stem Cell. 
Lian, G., and Sheen, V.L. (2015). Cytoskeletal proteins in cortical development and disease: 
actin associated proteins in periventricular heterotopia. Front Cell Neurosci 9, 99. 
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408. 
Lui, J.H., Hansen, D.V., and Kriegstein, A.R. (2011). Development and evolution of the human 
neocortex. Cell 146, 18-36. 
Lynn, B.D., Li, X., Cattini, P.A., Turley, E.A., and Nagy, J.I. (2001). Identification of 
sequence, protein isoforms, and distribution of the hyaluronan-binding protein RHAMM in 
adult and developing rat brain. J Comp Neurol 439, 315-330. 
Margolis, R.U., Margolis, R.K., Chang, L.B., and Preti, C. (1975). Glycosaminoglycans of 
brain during development. Biochemistry 14, 85-88. 
Masuda, K., Toda, T., Shinmyo, Y., Ebisu, H., Hoshiba, Y., Wakimoto, M., Ichikawa, Y., and 
Kawasaki, H. (2015). Pathophysiological analyses of cortical malformation using 
gyrencephalic mammals. Sci Rep 5, 15370. 
Matsumoto, N., Shinmyo, Y., Ichikawa, Y., and Kawasaki, H. (2017). Gyrification of the 
cerebral cortex requires FGF signaling in the mammalian brain. Elife 6. 
Miller, J.A., Ding, S.L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Ebbert, A., Riley, Z.L., 
Royall, J.J., Aiona, K., et al. (2014). Transcriptional landscape of the prenatal human brain. 
Nature 508, 199-206. 
Miron-Mendoza, M., Seemann, J., and Grinnell, F. (2010). The differential regulation of cell 
motile activity through matrix stiffness and porosity in three dimensional collagen matrices. 
Biomaterials 31, 6425-6435. 
Long et al,   30 May 2018 
 
 23 
Molyneaux, B.J., Arlotta, P., Menezes, J.R., and Macklis, J.D. (2007). Neuronal subtype 
specification in the cerebral cortex. Nat Rev Neurosci 8, 427-437. 
Morriss-Kay, G.M., Tuckett, F., and Solursh, M. (1986). The effects of Streptomyces 
hyaluronidase on tissue organization and cell cycle time in rat embryos. J Embryol Exp 
Morphol 98, 59-70. 
Mota, B., and Herculano-Houzel, S. (2015). BRAIN STRUCTURE. Cortical folding scales 
universally with surface area and thickness, not number of neurons. Science 349, 74-77. 
Naba, A., Clauser, K.R., Hoersch, S., Liu, H., Carr, S.A., and Hynes, R.O. (2012). The 
matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor 
extracellular matrices. Mol Cell Proteomics 11, M111 014647. 
Nagy, J.I., Hacking, J., Frankenstein, U.N., and Turley, E.A. (1995). Requirement of the 
hyaluronan receptor RHAMM in neurite extension and motility as demonstrated in primary 
neurons and neuronal cell lines. J Neurosci 15, 241-252. 
Nowakowski, T.J., Bhaduri, A., Pollen, A.A., Alvarado, B., Mostajo-Radji, M.A., Di Lullo, E., 
Haeussler, M., Sandoval-Espinosa, C., Liu, S.J., Velmeshev, D., et al. (2017). Spatiotemporal 
gene expression trajectories reveal developmental hierarchies of the human cortex. Science 
358, 1318-1323. 
Parrini, E., Conti, V., Dobyns, W.B., and Guerrini, R. (2016). Genetic Basis of Brain 
Malformations. Mol Syndromol 7, 220-233. 
Pollen, A.A., Nowakowski, T.J., Chen, J., Retallack, H., Sandoval-Espinosa, C., Nicholas, 
C.R., Shuga, J., Liu, S.J., Oldham, M.C., Diaz, A., et al. (2015). Molecular Identity of Human 
Outer Radial Glia during Cortical Development. Cell 163, 55-67. 
Pollen, A.A., Nowakowski, T.J., Shuga, J., Wang, X., Leyrat, A.A., Lui, J.H., Li, N., 
Szpankowski, L., Fowler, B., Chen, P., et al. (2014). Low-coverage single-cell mRNA 
sequencing reveals cellular heterogeneity and activated signaling pathways in developing 
cerebral cortex. Nat Biotechnol 32, 1053-1058. 
Rakic, P. (2009). Evolution of the neocortex: a perspective from developmental biology. Nat 
Rev Neurosci 10, 724-735. 
Reillo, I., de Juan Romero, C., Garcia-Cabezas, M.A., and Borrell, V. (2011). A role for 
intermediate radial glia in the tangential expansion of the mammalian cerebral cortex. Cereb 
Cortex 21, 1674-1694. 
Reiner, O. (1999). The unfolding story of two lissencephaly genes and brain development. Mol 
Neurobiol 20, 143-156. 
Richman, D.P., Stewart, R.M., Hutchinson, J.W., and Caviness, V.S., Jr. (1975). Mechanical 
model of brain convolutional development. Science 189, 18-21. 
Rilla, K., Pasonen-Seppanen, S., Rieppo, J., Tammi, M., and Tammi, R. (2004). The 
hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and 
epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol 123, 708-
714. 
Long et al,   30 May 2018 
 
 24 
Saito, T., Dai, T., and Asano, R. (2013). The hyaluronan synthesis inhibitor 4-
methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary 
tumor cells. Oncol Lett 5, 1068-1074. 
Schaefer, L., and Iozzo, R.V. (2008). Biological functions of the small leucine-rich 
proteoglycans: from genetics to signal transduction. J Biol Chem 283, 21305-21309. 
Schenk, J., Wilsch-Brauninger, M., Calegari, F., and Huttner, W.B. (2009). Myosin II is 
required for interkinetic nuclear migration of neural progenitors. Proceedings of the National 
Academy of Sciences of the United States of America 106, 16487-16492. 
Shinmyo, Y., Terashita, Y., Dinh Duong, T.A., Horiike, T., Kawasumi, M., Hosomichi, K., 
Tajima, A., and Kawasaki, H. (2017). Folding of the Cerebral Cortex Requires Cdk5 in Upper-
Layer Neurons in Gyrencephalic Mammals. Cell Rep 20, 2131-2143. 
Smart, I.H., Dehay, C., Giroud, P., Berland, M., and Kennedy, H. (2002). Unique 
morphological features of the proliferative zones and postmitotic compartments of the neural 
epithelium giving rise to striate and extrastriate cortex in the monkey. Cerebal Cortex 12, 37-
53. 
Solis, M.A., Chen, Y.H., Wong, T.Y., Bittencourt, V.Z., Lin, Y.C., and Huang, L.L. (2012). 
Hyaluronan regulates cell behavior: a potential niche matrix for stem cells. Biochem Res Int 
2012, 346972. 
Stahl, R., Walcher, T., De Juan Romero, C., Pilz, G.A., Cappello, S., Irmler, M., Sanz-Aquela, 
J.M., Beckers, J., Blum, R., Borrell, V., et al. (2013). Trnp1 regulates expansion and folding 
of the Mammalian cerebral cortex by control of radial glial fate. Cell 153, 535-549. 
Stenzel, D., Wilsch-Brauninger, M., Wong, F.K., Heuer, H., and Huttner, W.B. (2014). Integrin 
alphavbeta3 and thyroid hormones promote expansion of progenitors in embryonic neocortex. 
Development 141, 795-806. 
Sun, T., and Hevner, R.F. (2014). Growth and folding of the mammalian cerebral cortex: from 
molecules to malformations. Nat Rev Neurosci 15, 217-232. 
Tallinen, T., Chung, J.Y., Biggins, J.S., and Mahadevan, L. (2014). Gyrification from 
constrained cortical expansion. Proc Natl Acad Sci U S A 111, 12667-12672. 
Tallinen, T., Chung, J.Y., Rousseau, F., Girard, N., Lefevre, J., and Mahadevan, L. (2016). On 
the growth and form of cortical convolutions. Nature Physics 12, 588-593. 
Trochon, V., Mabilat-Pragnon, C., Bertrand, P., Legrand, Y., Soria, J., Soria, C., Delpech, B., 
and Lu, H. (1997). Hyaluronectin blocks the stimulatory effect of hyaluronan-derived 
fragments on endothelial cells during angiogenesis in vitro. FEBS Lett 418, 6-10. 
Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., 
Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based 
map of the human proteome. Science 347, 1260419. 
van Oers, R.F., Rens, E.G., LaValley, D.J., Reinhart-King, C.A., and Merks, R.M. (2014). 
Mechanical cell-matrix feedback explains pairwise and collective endothelial cell behavior in 
vitro. PLoS Comput Biol 10, e1003774. 
Long et al,   30 May 2018 
 
 25 
Vinas-Jornet, M., Esteba-Castillo, S., Gabau, E., Ribas-Vidal, N., Baena, N., San, J., Ruiz, A., 
Coll, M.D., Novell, R., and Guitart, M. (2014). A common cognitive, psychiatric, and 
dysmorphic phenotype in carriers of NRXN1 deletion. Mol Genet Genomic Med 2, 512-521. 
Wong, F.K., Haffner, C., Huttner, W.B., and Taverna, E. (2014). Microinjection of membrane-
impermeable molecules into single neural stem cells in brain tissue. Nat Protoc 9, 1170-1182. 
Zhang, S., Chang, M.C., Zylka, D., Turley, S., Harrison, R., and Turley, E.A. (1998). The 
hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem 273, 
11342-11348. 
Zhang, Z.N., Freitas, B.C., Qian, H., Lux, J., Acab, A., Trujillo, C.A., Herai, R.H., Nguyen 
Huu, V.A., Wen, J.H., Joshi-Barr, S., et al. (2016). Layered hydrogels accelerate iPSC-derived 
neuronal maturation and reveal migration defects caused by MeCP2 dysfunction. Proc Natl 
Acad Sci U S A 113, 3185-3190. 
Zilles, K., Armstrong, E., Schleicher, A., and Kretschmann, H.J. (1988). The human pattern of 
gyrification in the cerebral cortex. Anat Embryol 179, 173-179. 
Zilles, K., Palomero-Gallagher, N., and Amunts, K. (2013). Development of cortical folding 
during evolution and ontogeny. Trends Neurosci 36, 275-284. 
  
Long et al,   30 May 2018 
 
 26 
Acknowledgments 
We apologize to all researchers whose work could not be cited due to space limitation. We are 
grateful to the Services and Facilities of the MPI-CBG for the outstanding support provided, 
notably Jussi Helppi and his team of the Animal Facility, Holger Brandl and Lena Herseman 
from the Scientific Computing Facility and Jan Pechyl and his team of the Light Microscopy 
Facility. We are also grateful to Andreas Dahl and Suzanne Reinhardt from the Deep 
Sequencing Group, and Hella Hartman from the Light Microscopy Facility, both at the Centre 
for Regenerative Therapies Dresden (CRTD). We would also like to thank Dianne Gerrelli, 
Steve Lisgo and their teams at the HDBR along with James Nicoll and his team at BRAIN UK 
for the invaluable support from these resources, Robert Lachmann for providing human 
neocortical samples for the pilot experiments, Carsten Werner and Jens Friedrichs from the 
IPF for their assistance and expertise with the AFM experiments. We thank Mareike Albert for 
advice with qPCR, Elena Taverna for useful suggestions, Romy Schuster for help with 
immunostaining, and members of the Huttner lab for critical discussion and review of the 
manuscript. B.N. would like to thank the Wellcome Trust for the Sir Henry Wellcome 
Postdoctoral Fellowship. W.B.H. was supported by grants from the DFG (SFB 655, A2) and 
the ERC (250197). The supplementary materials contain additional data. RNA-seq raw data 
have been deposited with the Gene Expression Omnibus under accession codes GSE106640. 
 
Contributions 
K.R.L and W.B.H. designed the study, analyzed the data and wrote the manuscript, with input 
from the other authors. K.R.L. performed and analyzed the experiments, collaborating with 
B.N. in the AFM and hydrogel experiments, with M.F. in the transcriptome analyses, and with 
N.K. and B.L. in the ferret experiments. A.K. and P.W. provided human neocortex tissue. 
W.B.H. supervised the study. 
 
Competing interests 
The authors declare no competing financial interests. 
Long et al,   30 May 2018 
 
 27 
Figure Legends 
 
Figure 1. HAPLN1, lumican and collagen I selection and IF. 
(A) Stepwise exclusion parameters to the datasets of core matrisome genes (Naba et al., 
2012) that were differentially expressed between 13-17 GW human neural progenitor cells 
(NPCs) than E14.5 mouse NPCs and E9.5 mouse neuroepithelial cells (NECs), to home-in on 
genes specifically expressed in human NPCs that were downregulated in mouse neural 
development. See also Table 1. 
(B) DAPI staining (blue) and either HAPLN1, lumican or collagen I IF (grey, as indicated) of 
13 GW human neocortex (huNcx) (top row) and E14.5 mouse neocortex (bottom row). Scale 
bars: 200 µm. 
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Figure 2. Addition of the ECM components HLC to 11-14 GW human neocortex in 
organotypic slice culture and FFTC induces in vitro folding of the CP. 
Organotypic slice cultures (A, C, D) and FFTCs (B, E-I) of 11-14 GW huNcx subjected to 
treatment for 24 h. 
(A) DAPI staining of 13 GW human neocortex embedded in collagen I alone (Control), with 
addition of HAPLN1 and lumican (HAPLN1 + lumican) and with only HAPLN1 (HAPLN1). 
(A, B) Lines on left of panel indicate the CP and the ventricular surface (VS). 
(B) DAPI staining of 13 GW huNcx in FFTC subjected to control and HLC-treatment. 
(C) Quantification of Gyrencephalic Index (GI) of 11-14 GW huNcx in FFTC subjected to 
the indicated treatments. *, P= 0.04; **, P =0.0015. 
(D, E) DAPI staining (blue) and laminin IF (red) of CP of 13 GW huNcx in organotypic slice 
cultures (D) and FFTC (E). 
(F) Quantification of GI of 11-14 GW huNcx in FFTC subjected to control and HLC-
treatment. ***, P =<0.0001. 
(G) DAPI staining (blue) and nestin IF (grey) of 13 GW huNcx . Dashed boxes delineate 
panels on right. 
(H) Quantification of GI in 11-14 GW huNcx in FFTC subjected to the indicated conditions. 
***, P=0.0008. 
(I) Still images at the indicated time points of time-lapse imaging of 12 GW huNcx in 
organotypic slice culture subjected to control (top) and HLC-treatment (bottom). Arrowheads 
indicate sulcus between forming gyri. 
(A, B, D, E, G, I) Scale bars: (A, B, D, E, I) 200 µm, (G) 50 µm. (B) and (G) are 
independent experiments (ind. exp.). 
(C, F, H) Statistical tests; one-way ANOVA (C, H), unpaired Student’s t-test (F). Error bars, 
SD; ns, P >0.05. Data points in (C, H) 3-4 ind. exp. (1 fetus/exp.) with 1-2 slice (C) or 
FFTCs (H) per condition per fetus, and in (F) 8 ind. exp. (1 fetus/exp.) with 1-3 FFTCs per 
condition per fetus. 
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Figure 3. HLC IF in 18 GW human neocortex, and HLC and HA IF in 22 GW and 38 
GW human neocortex CP. 
(A) DAPI staining (blue) and either HAPLN1, lumican or collagen 1 IF (grey, as indicated) 
of 18 GW huNcx. Yellow boxes delineate areas in panels on right. 
(B, C) DAPI staining (blue) and co- IF of HA (green) and either HAPLN1, lumican or 
collagen 1 (grey, as indicated) of 22 GW CP (B), containing a nascent, inherent fold, and 38 
GW CP (C) in the gyrus and sulcus (as indicated). (C, far left) Image of 38 GW section used 
for CP images (right). Yellow dashed line delineates CP surface, blue arrows indicate areas 
imaged. 
(A-B) Scale bars: (A) 200 µm, (B) 500 µm and (C) 50 µm for CP insets and 1 cm for entire 
section image. 
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Figure 4. HLC-induced folding increases and requires HA at 11-14 GW and 22 GW. 
(A, A’) DAPI staining (blue) and double IF for HAPLN1 (yellow) and HA (red) of 14 GW 
huNcx in FFTC subjected to control (top) and HLC-treatment (bottom) for 24 h. Top and 
bottom dashed boxes delineate CP and VZ panels, respectively, in A’. White dashed lines 
outline unfolded (control) and folded (HLC-treatment) CP surface. (B) Quantification of the 
CP/VZ ratio of HA immunoreactivity of 11-14 GW huNcx in FFTC subjected to the 
indicated treatments for 24 h. ***, P=0.0009; **, P=0.0032. (C) Quantification of the CP/VZ 
ratio of HA immunoreactivity of 13-15 GW huNcx in FFTC subjected to control and HLC-
treatment for 8 and 16 h. *, P=0.0128 (8 h); *, P=0.0394 (16 h). 
(D) DAPI staining (blue) and HA IF (red) of 12 GW huNcx in FFTC subjected to control 
(left), HLC-treatment (middle) and HLC-treatment in the presence of hyals (right) for 24 h. 
Dashed boxes delineate panels below. 
(E) Quantification of GI of 12-14 GW huNcx in FFTC subjected to the indicated treatments 
for 24 h, except for the condition HLC-treatment + hyaluronidases @ 24 h (HLC-treatment 
for 48 h with addition of hyals at 24 h). ***, P=<0.0001 (control vs. HLC-treatment) and 
P=0.0005 (control vs. HLC-treatment + chondABC); **, P=<0.0021. 
(F) Quantification of GI of 14-18 GW huNcx in FFTC subjected to indicated treatments. ***, 
P=0.0008, P=0.0008. 
(G-K) 22 GW huNcx in FFTC was subjected to the indicated treatments for 4 days, except 
for the condition non-cultured in (H). (G, H) Quantification of GI. *, P=0.0124; **, 
P=0.0066-0.0074; ***, P=0.0009. (I-K) DAPI staining of the CP upon control (I top, J left, 
K left), HLC-treatment (I middle, J right) and hyals plus HAS inhibitor (I right, K right). 
White dashed lines outline unfolded or folded CP surface; arrowheads indicate sulcus. 
(A, A’, D, I, J, K) Scale bars: (A, D, E) 200 µm, (A’ and insert in D) 50 µm and (I-K) 500 
µm. (B, C, E-H) Statistical tests; one-way ANOVA (B, E-H), two-way ANOVA (C). Error 
bars, SD; ns, P >0.05. Data points in (B) 8 ind. exp. (1 fetus/exp.) with 1-3 FFTCs per 
condition per fetus; in (F) 5-6 ind. exp. (1 fetus/exp.) with 1-3 FFTCs per condition per fetus; 
in (G) 3 ind. exp. (1 fetus/exp.) with 1 FFTC/exp.  
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Figure 5. HLC-treatment replicates certain aspects of 22 GW physiological nascent 
folds and increases ECM stiffness. 
(A, B) DAPI staining (blue) and double IF for TBR1 (yellow) and CTIP2 (red) of 22 GW 
huNcx not subjected to culture (A). Note the nascent fold of the CP, and 15 GW huNcx in 
FFTC subjected to control and HLC-treatment (B) (2 examples shown). 
(C-E) 11-14 GW huNcx in FFTC subjected to control and HLC-treatment for 24 h. (C) 
Representative images showing DAPI staining of 13 GW huNcx CP of control (left), CP 
sulcus upon HLC-treatment (middle), and CP gyrus upon HLC-treatment (right). (D) 
Frequency distribution histogram for the distance between nuclei within the CP. (E) 
Quantification of the distance between nuclei within the CP. Data are presented in a whisker 
plot showing the minimum, mean and maximum values. *, P=0.02 (control vs. gyrus), 
P=0.0148 (sulcus vs. gyrus). 
(F-H) AFM measurements in sections of 13 GW (G, H) and 12-14 GW (F) huNcx in FFTC 
subjected to control (G, H, left; F) and HLC-treatment (G, H, right; F) for 16 h (G) and 24 h 
(H, F), and of non-cultured 22 GW huNcx (I). Each heatmap square in (G, H, I) shows 9 
Young's modulus values in the position the measurement was taken (see range of values from 
blue (lowest) to yellow (highest)). White dashed lines in (G, H, I) outline unfolded or folded 
CP surface; arrowheads indicate sulci. (F) Quantification of AFM measurements in 12-14 
GW huNcx samples in FFTC (1 FFTC/condition). *, P=0.0198. (J) Quantification of the 
range of AFM measurements in 22 GW huNcx subjected to the indicated treatments for 4 
days. Y axis represents the range of the Young’s modulus values measured (in Pa). 
(A, B, C, G, H, I) Scale bars: (A, B, D, J) 200 µm, (C) 50 µm and (I) 500 µm. (E, F) 
Statistical test; one-way ANOVA. Error bars, SEM. Data points in (D, E), 4 ind. exp. (1 
fetus/exp.) with 1 FFTC per condition per fetus, in (J) 2 ind. exp. (1 fetus/exp.) with 1 FFTC 
per condition per fetus.  
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Figure 6. HLC-induced folding requires the HA-receptor CD168 and downstream ERK 
signaling. 
(A, B) DAPI staining (blue) and triple IF for HA (green) and the HA-receptors CD168 (grey) 
and CD44 (magenta) in non-cultured 13 GW huNcx wall (A) and 22 GW human CP (B). 
(C) DAPI staining of 14 GW huNcx in FFTC subjected to control (top left), HLC-treatment 
(top right), HLC-treatment plus CD44 antibody (lower left) and HLC-treatment plus CD168 
antibody (lower right) for 24 h. 
(D) Quantification of GI in 12-15 GW huNcx in FFTC subjected to the indicated treatments 
for 24 h. **, P=0.0092; *, P=0.108. 
(E) Quantification of the CP/VZ ratio of HA immunoreactivity of 11-14 GW huNcx in FFTC 
subjected to the indicated treatments for 24 h. *, P<0.05. 
(F) Quantification of pERK immunoreactivity in the CP relative to control of 12-15 GW 
huNcx in FFTC subjected to the indicated treatments for 24 h, *, P=0.0194. 
(G) Quantification of pERK immunoreactivity in the CP relative to control of 12-15 GW 
huNcx in FFTC subjected to the indicated treatments for 8 and 24 h. Blue dashed line 
indicates control (set to 1.0). 
(H) Quantification of the ratio of pERK immunoreactivity in gyri compared to their 
neighboring sulci of 12-16 GW huNcx in FFTC subjected to HLC-treatment for 24 h. Blue 
dashed line indicates control (set to 1.0). 
(I) Quantification of pERK immunoreactivity in the CP of 13-14 GW huNcx in FFTC 
subjected to the indicated treatments for 24 h, relative to control indicated by the blue dashed 
line (set to 1.0). *, P=0.0308. 
(J) Quantification of GI in 12-16 GW huNcx in FFTC subjected to control, HLC-treatment 
and HLC-treatment plus ERK inhibitor for 24 h. **, P=0.0066 (control vs, HLC-treatment), 
P=0.0074 (HLC-treatment vs. HLC-treatment + ERK inhibitor). 
(K) DAPI staining (blue) and pERK IF (grey) of 16 GW huNcx in FFTC subjected to 
control, HLC-treatment and HLC-treatment plus ERK inhibitor for 24 h. 
(A-C, K) Scale bars: 200 µm. 
(D-G, I, J) Statistical test; one-way ANOVA (D-F, I) and Student’s t-test (G, J). Error bars, 
SD; ns, P >0.05. Data points in (D-J) 3 ind. exp. (1 fetus/exp.) with 1 FFTC per condition per 
fetus.  
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Figure 7. HLC-induced folding is perturbed in specific human neocortex samples with 
NDDs. 
(A) DAPI staining of the CP of 16 GW huNcx with DS in FFTC subjected to control (left) 
and HLC-treatment (right) for 24 h. 
(B) Quantification of GI in 12-17 GW huNcx samples with altered neocortex development as 
indicated, subjected to control (open circles) and HLC-treatment (filled circles) in FFTC for 
24 h. ***, P=0.0005. 
(C-E) DAPI staining (blue) and HA IF (green) in 14 GW DS (C), 12 GW PME (D) and 
2p16.3 microdeletion (E) huNcx in FFTC subjected to control (left) and HLC treatment 
(right). 
(F-I) 21 GW DS sample subjected to control (F, top, I left) HLC-treatment (F, middle, I, 
right) and the indicated HA level-reducing treatment (F, bottom) for 4 days. (F) White 
dashed lines outline the unfolded or folded CP surface; white asterisk indicates tear in CP 
(bottom). (G) Quantification of GI in 21 GW huNcx with DS in FFTC subjected to the 
indicated treatments for 4 days. **, P=0.0014-0.0076. (H) Quantification of the CP/VZ ratio 
of HA immunoreactivity of 12-16 GW and 21 GW huNcx with the indicated NDDs in FFTC 
subjected to HLC-treatment for 24 h (12-16 GW) or 4 days (21 GW). Bars indicate one fetal 
sample per indicated NDD, therefore values are shown relative to control (control set to 1.0) 
and without statistical analysis. For each sample, an average of 3 cryosections per condition 
were analyzed. Color of the bars indicate huNcx samples where GI was not significantly 
increased (white) or was significantly increased after HLC-treatment (grey). (I) DAPI 
staining and HA IF from CP of 21 GW DS sample subjected to control (left) and HLC-
treatment (right). 
(A, C-F, I) Scale bars: (A, F) 500 µm, (C-E) 200 µm, (I) 50 µm. 
(B, G) Statistical test; two-way ANOVA (B), one-way ANOVA (G). Error bars, SD, ns = P 
>0.05. Data points in (B, G) 1 ind. exp. (1 fetus/exp.) with 3-6 FFTCs per condition per fetus. 
  
Long et al,   30 May 2018 
 
 34 
Table 1. 9 genes: Mouse NPCs no/low expression FPKM <1. 
  
Gene ID Mouse 
NECS 
Mouse 
aRG 
Mouse 
bRGs 
Mouse 
bIPs 
 
Mouse 
Neurons 
Human 
aRG 
Human 
bRG 
Human 
Neurons 
COL1A2 10.282964 0.171441 0.0415107 0.104064 0.115875 10.4022 4.27089 1.63804 
HAPLN1 25.88738 0.103337 0.0826579 0.0368054 0.1021 8.0011 2.95787 0.618723 
LUM 42.58198 0.11563 0.0597305 0.0444983 0.24573 4.41632 1.78397 0.53201 
TINAG 2.761322 0.11633 0.124181 0.162185 0.168129 3.77847 3.24168 1.70318 
COL3A1 4.96066 0.101161 0.0612023 0.0661498 0.0410923 3.43414 2.13655 1.27261 
EGFLAM 3.076604 0.0654521 0.117693 0.239263 0.137794 1.50781 0.517271 0.150278 
RSPO2 2.320142 0.0526038 0.0619082 0.0446231 0.239362 1.44148 0.968042 0.789062 
PCOLCE2 22.2624 0.184318 0.0904057 0.277552 0.239362 0.86201 0.651806 0.504199 
COL23A1 3.689042 0.295979 0.105298 0.101661 0.154592 0.252818 0.449853 0.0507757 
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Methods 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Wieland Huttner (huttner@mpi-cbg.de). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Tissue 
Human tissue 
Human fetal brain tissue was obtained from three sources. First, from the Klinik und 
Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Carl Gustav Carus of 
the Technische Universität Dresden, following elective pregnancy termination and informed 
written maternal consents, and with approval of the local University Hospital Ethical Review 
Committees. The age of fetuses ranged from 11 to 13 GW as assessed by ultrasound 
measurements of crown-rump length and other standard criteria of developmental stage 
determination. The second source was the Human Development Biology Resource (HDBR). 
The human embryonic and fetal material was provided by the Joint MRC/Wellcome Trust 
(grant # 099175/Z/12/Z) Human Developmental Biology Resource (www.hdbr.org). The 
HDBR provided fresh tissue from fetuses aged 13-22 GW, (13 GW, n = 3; 14 GW, n = 11; 
15 GW, n = 9; 16 GW, n = 2; 18 GE, n = 2; 22 GW, n = 3). Several samples with 
neurodevelopmental defect were also obtained. A sample affected by methamphetamine 
abuse was obtained from the Klinik in Dresden (12 GW, n = 1), and the HDBR provided 5 
samples with Down syndrome (12 GW, n = 2; 16 GW, n = 1; 17 GW, n = 1; 21 GW, n = 1) 
and 1 sample with a 2p16.3 microdeletion (16 GW, n = 1). Due to protection of data privacy, 
neither gender identity nor sex of the human fetuses of which neocortex tissue was obtained 
can be reported. Neither gender identity nor sex of the human fetuses is likely to be of 
relevance for the results obtained in the present study. 
 
Human fetal brain tissue was dissected in PBS and used immediately for culture or fixation 
when obtained from Dresden. When obtained from HDBR, tissue was dissected and shipped 
in Hibernate E media (Gibco A1247601). Upon arrival, all tissue was cultured in slice culture 
medium (SCM - see the following section) for 2-3 h prior to any further manipulation. All 
tissue was fixed for at least 24 h at 4°C in 4% (wt/vol) paraformaldehyde (PFA) in 120 mM 
phosphate buffer (pH 7.4). The HDBR also provided fixed neocortical material from 3 
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fetuses aged 13, 18, 22 and 24 GW. This tissue was placed into 4% PFA (wt/vol) in 120 mM 
phosphate buffer immediately after dissection and shipped within this fixative (fixation was 
for at least 24 h). The third source provided fixed tissue sections (38 GW). These were 
obtained from University Hospital Southampton as part of the UK Brain Archive Information 
Network (BRAIN UK) which is funded by the Medical Research Council and Brain Tumour 
Research. Sample size was determined from the number of fetuses from whom neocortex 
tissue was obtained, and is indicated in the relevant figure legends. 
 
Ferret tissue 
Timed-pregnant ferrets were obtained from Marshall BioResources and housed at the BMS 
of MPI-CBG. For the analysis of embryonic day (E) 33-36 ferret embryos, pregnant ferrets 
were deeply anesthetized by subcutaneous injection of ketamine (40 mg/kg) plus xylazine (2 
mg/kg); the embryos were collected in PBS, and the adult ferret was then sacrificed by 
intracardiac injection of T‐61 (0.3 ml/kg). Embryonic ferret neocortex was then used for the 
preparation of organotypic slice cultures or FFTCs (E33-36) or fixed immediately in 4% PFA 
in phosphate buffer. Postnatal day (P) 9 and P15 ferret pups were deeply anesthetized by 
intraperitoneal injection of ketamine (40 mg/kg) plus xylazine (2 mg/kg), and then either 
sacrificed by decapitation (followed by dissection in PBS for FFTC) or by intracardial 
perfusion using 4% PFA in phosphate buffer at 37oC. Perfusions were performed with 
additional anesthetization with 4% isoflurane. 
 
Mouse tissue 
All mice used were wild-type C57BL/6JOlaHsd. E0.5 was set at noon of the day on which 
the vaginal plug was observed. All experiments were performed in the dorsolateral neocortex 
of E14.5 embryos, and all images were acquired and analyzed from coronal sections of the 
frontal and parietal neocortex.  
 
Mouse and ferret neocortical tissue for fixation, either prior to or after manipulation, was 
fixed for at least 24 h at 4°C in 4% (wt/vol) PFA in 120 mM phosphate buffer (pH 7.4). 
 
All animal experimental procedures were designed and conducted in agreement with the 
German Animal Welfare Legislation. Animals used for this study were kept pathogen-free at 
the Biomedical Services Facility (BMS) of the MPI-CBG.  
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METHOD DETAILS 
Organotypic slice cultures and free-floating tissue cultures 
Organotypic neocortical slice cultures and free-floating tissue (FFT) neocortex cultures were 
performed as previously described (Fietz et al., 2012; Schenk et al., 2009; Wong et al., 2014). 
The media used for both types of cultures was slice culture medium (SCM): 84 ml of 
Neurobasal medium (Gibco, 21103049) supplemented with 10 ml rat serum (for mouse and 
ferret cultures) or 10 ml of KOSR (for human cultures, Gibco, 10828028), 1 ml glutamine (2 
mM), 1 ml Penstrep (100x), 1 ml N-2 (100x) (Gibco, 17502048), 2 ml B-27 (50x) (Gibco, 
17504044) and 1 ml of 1 M HEPES-NaOH, pH 7.2, to yield a final volume of 100 ml. 
 
Briefly, for organotypic slice cultures, neocortical tissue was embedded in 3% low melting 
point agarose (Sigma, A2790), cut on a vibratome to 250 µm-thick slices, and embedded in a 
collagen I-based hydrogel (Cellmatrix type I-A, Kyowa chemical products, 631-00651) (Wong 
et al., 2014) before culture at 37°C in the presence of humidified 40% O2 / 5% CO2 /55% N2. 
Hence, as all organotypic slice cultures were embedded in collagen I (100 µl per slice, except 
for live imaging, see below), this condition applies to the control. As indicated, recombinant 
human HAPLN1 (R&D, 2608-HP-025; 100 µg|ml stock solution in PBS) and recombinant 
human lumican (R&D, 2846-LU-050; 200 µg|ml stock solution in PBS) were added to the 
collagen I embedding solution (final collagen concentration 1.5 mg/ml in DMEM) to yield a 
final concentration of 5 µg/ml each. Control received the equivalent volume of PBS. For the 
laminin and collagen IV condition, recombinant laminin-211 (BioLamina, LN211; 100 µg|ml 
stock solution) and native human collagen IV (abcam, ab7536; 1 mg|ml stock solution) were 
added to the collagen I embedding solution to yield a final concentration of 5 µg/ml each. The 
concentration of 5 µg/ml was chosen for ECM components in light of previous reports using 
various ECM components in vitro (van Oers et al., 2014; Zhang et al., 2016). Each slice then 
received 1 ml of SCM followed by culture. 
 
For FFTCs, tissue was manually cut to 2000-2500 µm-thick pieces (tangential dimension), 
placed into a rotating flask with 1.5 ml SCM, and incubated at 37°C in the presence of 
humidified 40% O2 / 5% CO2 /55% N2. Control FFTCs had nothing added to the SCM. For 
the HLC-treatment condition, recombinant human HAPLN1 (R&D 2608-HP-025), 
recombinant human lumican (R&D 2846-LU-050) and native human collagen I (abcam 
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ab7533; 1 mg|ml stock solution) were added to the SCM. Each ECM component had a final 
concentration of 5 µg/ml.  
 
Other conditions for FFTCs were as follows. For hyaluronidase experiments, a cocktail of 
hyaluronidases added to the SCM was used: hyaluronidase-type-1 (Sigma, H3506) at a final 
concentration of 50 µg/ml, hyaluronidase-type-IV (Sigma, H3884) at a final concentration of 
50 µg/ml, and hyaluronidase-type-VI (Sigma, H3631) at a final concentration of 50 units/ml. 
To inhibit synthesis of HA, the HA synthase (HAS) inhibitor 4-methylumbelliferone (Sigma, 
M1381) was added to the SCM at a final concentration of 0.2 mM. Hyaluronidase and HAS 
inhibitor treatments were also applied in combination, as indicated. To target chondroitin 
sulfate glycosaminoglycan components of the ECM, chondroitinase ABC (Sigma, C3667) 
was added to the SCM at a final concentration of 0.2 units/ml. To inhibit proliferation, 
mitomycin C (Tocris, 3258/10) was added to the SCM at a final concentration of 10 µg/ml. 
To inhibit ERK activity, the selective ERK inhibitor FR 180204 (Tocris, 3706) was added to 
the SCM at a final concentration of 3 mM. The concentrations selected for the above 
enzymes and inhibitors were selected in light of previous reports (Hoogendoorn et al., 2007; 
Saito et al., 2013; Trochon et al., 1997).  
 
In addition to the above, the following conditions for FFTCs were used. A soluble basement 
membrane extract, Geltrex (Gibco, A15696), was added to the SCM at a final concentration 
of 5 µg/ml. For ferret FFTCs as indicated, HA (1-3%, Advanced Biomatrix, 5011-3) was 
used at a final concentration of 10 µg/ml. This concentration was chosen to ensure that the 
HA would saturate the recombinant HAPLN1 added to the FFTCs (5 µg/ml). The CD44 
antibody (abcam, ab25340) and the CD168 antibody (abcam, ab185728) were each added to 
the SCM at a final concentration of 30 µg/ml. For quantification of cells in S-phase, EdU was 
added to the SCM at a final concentration of 1 µg/ml (Click-iT EdU Alexa Fluor 647 
imaging kit, Invitrogen, C10340) 1 hour prior to fixation. 
 
Cryosectioning and immunostaining 
Fixed tissue for cryosectioning was infiltrated with 30% sucrose overnight at 4oC before 
being embedded in Tissue-Tek (Sakura Finetek) and stored at −20°C. Cryosections were cut 
at 20 µm and stored at −20 °C until required. Sections for immunostaining that required 
antigen retrieval were subjected to 10 mins at 95oC in citrate buffer (pH 6.1, Target Retrieval 
Solution, DakoCytomation). All sections were then treated with blocking solution (PBS 
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supplemented with 10% goat serum, containing a final concentration of 0.1% Triton X-100) 
for 30 mins before the addition of the primary and appropriate secondary antibodies, both 
diluted in blocking solution. The primary antibodies used were as follows: nestin (abcam, ab 
27952), HAPLN1 (abcam, ab181997), HA (abcam, ab53842), lumican (abcam, ab168348), 
Col1a2 (abcam, ab96723), pVim (abcam, ab22651), CD168 (abcam, ab185728), CD44 
(abcam, ab119348), CTIP2 (abcam, ab18465), TBR1 (abcam, ab31940), PCNA (Millipore, 
CBL407), phospho-p44/42 MAPK (Erk1/2) (cell signaling, 9101), Phospho-p90RSK 
(Ser380) (D3H11) (cell signaling, 11989) and Penta His-tag (Qiagen, 34660). All antibodies 
were used at a 1/100 dilution. The secondary antibodies used were conjugated to Alexa Fluor 
488, 568 and 647 (Invitrogen), and all were used at 1/1000. EdU staining was performed 
using the Click-iT EdU Alexa Fluor 647 imaging kit (Invitrogen, C10340). All sections were 
counterstained with DAPI (Sigma, 1:1000) and mounted in Mowiol (Merck Biosciences). 
Sections were then imaged using a Zeiss LSM 700 inverted confocal microscope and a Zeiss 
Plan-Apochromat 20x 0.8 objective. For 22 GW human samples and P9 and P15 ferret 
samples, sections were first imaged using a Zeiss Axio Scan wide-field microscope and Zeiss 
Plan-Apochromat 10x 0.45 objective prior to selecting sections for imaging with the above 
confocal microscope. Images shown are maximum intensity projections of 11 optical sections 
from a 10 µm z-stack. 
 
Laser capture microdissection 
Laser capture microdissection (LCM) was performed in a similar manner as described 
previously (21). Human fetal neocortex tissue was cultured for 16 h (FFTC) with and without 
HLC-treatment, immediately frozen on dry-ice, and stored at –80oC. The tissue was then 
embedded in Tissue-Tek and cut at 30 µm sections on a cryostat. Cryosections were mounted 
onto nuclease-free MembraneSlide NF 1.0 PEN (Zeiss 415190-9081-000). Immediately prior 
to LCM, slides were rinsed for 30 sec in 70% (vol/vol) ice-cold ethanol, incubated for 30 sec 
in 1% cresyl violet in 100% (vol/vol) ethanol, and washed twice for 30 sec each in 100% 
(vol/vol) ethanol. Sections were then immediately subjected to LCM using an Axiovert 200M 
microscope equipped with a PALM LCM MicroBeam system (Zeiss) and a Zeiss Fluar 5x 
0.25 objective. For each cryosection, multiple square or rectangular areas of the cortical plate 
were isolated, with an edge length of 350-400 µm (tangential dimension) by 200-400 µm 
(radial dimension), and collected using AdhesiveCap tubes (Zeiss 415190-9201-000). Three 
to four tubes were obtained per sample. Each tube received 350 µl of RLT buffer (from the 
RNAeasy Mini kit Qiagen), was immediately stored on dry-ice and then transferred to –80oC.  
Long et al,   30 May 2018 
 
 40 
 
RNAseq library preparation 
Total RNA was extracted using the RNAeasy Mini kit (Qiagen), and polyadenylated mRNA 
was enriched with the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England 
Biolabs) according to the manufacturer's instructions. The cDNA and second strand synthesis 
as well as the library preparation (consisting of cDNA fragmentation, end repair, A-
tailing, ligation of sequencing adapters, indexing by PCR amplification for 15 cycles) were 
performed using the NEBNext Ultra II Directional RNA Library Prep Kit Illumina (New 
England Biolabs). Libraries were purified using XP beads (Beckman Coulter), quantified by 
Fragment Analyzer (AATI) and subjected to Illumina 75-bp single end sequencing on the 
Illumina Nextseq500 platform providing a minimum of 21 Mio reads per sample. 
Transcriptome data analysis 
Reads were checked for their overall quality using FastQC (v0.11.2). Alignments of reads 
against the human genome reference assembly GRCh38 and quantification of genes of the 
Ensembl release v88 were done using STAR (v2.5.2b). For the verification of technical 
duplicates, duplicated reads identified using Picard MarkDuplicates (v2.10.2) were analyzed 
with dupRadar (v1.6.0). Differential gene expression analysis on raw counts was performed 
with DESeq2 (v1.16.1) using a cutoff first of P <0.01 and then of P <0.05. The resulting list 
of 438 differentially expressed genes obtained with the latter cutoff was tested for enrichment 
in GO terms and pathways (KEGG, Reactome) on a 1% q-value level. 
qPCR  
Total RNA was isolated using the RNAeasy Mini kit (Qiagen) according to the 
manufacturer’s guidelines. cDNA was synthesized using random hexamers and Superscript 
III Reverse Transcriptase (Life Technologies). qPCR was performed using the Light Cycler 
SYBR Green Master mix (Roche) on a Light Cycler 96 (Roche), using the following settings: 
95oC for 15 min, followed by 40 cycles at 95oC for 30 sec, at 60oC for 30 sec and at 72oC for 
30 sec. Fold change in mRNA levels of each gene was determined relative to HPRT1 and 
then relative to control, using the ∆∆Ct method (Livak and Schmittgen, 2001). Primer 
sequences are provided in Table S2. 
Atomic force microscopy 
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Atomic force microscopy (AFM) was used to determine the Young’s moduli of various 
regions of the CP (i) in human 11-14 GW neocortex tissue after 8, 16 and 24 h of FFTC, (ii) 
in human 22 GW neocortex tissue that was frozen without fixation at the HDBR, shipped on 
dry-ice and stored at –80°C, and (iii) in ferret E33 neocortex tissue after 24 h of FFTC. To 
cut thin sections of the relatively soft human fetal neocortex that are required for AFM, and 
to be able to determine tissue stiffness preferentially with regard to ECM-cell interactions, 
samples underwent two freeze-thaw cycles as follows. Following FFTC, samples were frozen 
on dry-ice and stored at –80°C. The frozen FFT samples and the frozen human 22 GW 
neocortex tissue were thawed (completion of first freeze-thaw cycle), embedded in Tissue-
Tek at room temperature, again frozen on dry-ice, and stored at –80°C. Cryosections were 
then cut at a thickness of 100 µm and adhered to glass slides suitable for AFM (Superfrost 
Plus, Thermo Scientific). The samples were then stored at –20°C until analysis. Immediately 
prior to performing the AFM measurements, the cryosections were defrosted under laminar 
flow (completion of second freeze-thaw cycle) and air-dried before being gently submerged 
in PBS. The NanoWizard II AFM (JPK Instruments) was mounted on an Axio Observer D.1 
microscope (Zeiss) to allow visualization of the cryosections and correct positioning of the 
AFM tip. Experiments were performed at room temperature (held at 21°C). AFM 
measurements were performed using silicon nitride cantilevers with a nominal spring 
constant of 80 mN/m (PNP-TR-TL-Au; Nanoworld) with a 10 µm diameter silica bead 
(Kisker Biotec GmBH) adhered to the tip as reported previously (Krieg et al., 2008). Spring 
constants were calibrated before measurements using the equipartition theorem (Hutter and 
Bechhoefer, 1993). For indentation measurements, force-distance curves were taken in closed 
loop, constant height mode with an approach and retract velocity of 5 µm s−1, a contact force 
of 2 nN, and a z-length of 30 µm. Each data point was generated by taking 9 force-distance 
curves in a square shape of 30 µm x 30 µm (see Fig. 3a, b, d). A minimum of three data 
points were taken for each cryosection, and a minimum of 3 cryosections were measured per 
piece of tissue. The Young’s modulus (E) was calculated from the approach force-distance 
curves via the JPK Instruments data processing software. A Hertz fit was applied assuming a 
spherical indenter of radius (R) 5 µm, and a Poisson’s ratio () of 0.5 according to the 
following equation: 
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where  is the indentation and F is the force. 
 
Live imaging 
Live imaging was carried out on organotypic 250 µm-thick vibratome slice cultures of 12-13 
GW human neocortex tissue. Instead of embedding in a collagen I-based hydrogel, slices were 
embedded in a poly-(ethylene glycol) (PEG)-based hydrogel. To this end, a 0.07 g/ml PEG 
diacrylate (PEGDA700) solution in DMEM/F12 medium was prepared, which contained 0.1% 
(wt/vol) 2-hydroxy-2-methylpropiophenone as a photoinitiator to trigger polymerization (see 
below). This PEG hydrogel was used for two reasons. First, it is not an ECM component and 
is bio-inert and therefore does not interact with the recombinant HLC proteins added. Second, 
it has little to no auto-fluorescence. The three ECM components, recombinant HAPLN1, 
recombinant lumican and native collagen I, were then added to this solution to give the same 
final concentrations as specified above, 5 µg/ml each. Control samples (without HLC) received 
the equivalent volume of PBS to ensure that the final concentration of the hydrogel was the 
same. The neocortical slices were then transferred to the imaging dishes (Petri dish 35 x 14 
mm, including Microwell no.1.5 cover glass (Wong et al., 2014)) and immersed in 100 µl of 
this hydrogel±ECM precursor mix, which was immediately polymerized by exposure to 
ultraviolet light for five seconds (8000 mW/cm², Delolux 04, Delo GmBH). After 
polymerization, each dish received 1 ml of SCM. 
 
Two types of live imaging were used, 2-photon imaging and dark-field imaging. For 2-photon 
imaging, the fluorescent far-red nuclear dye DRAQ5 (5 µM in SCM, eBioscience, 65-0880) 
was used. This was added to the slices for 30 min prior to the PEG hydrogel embedding, after 
which the slices were washed in SCM to remove excess DRAQ5, as per manufacturer’s 
guidelines. Slices were then embedded in the PEGDA solution, as described above. Slices were 
subjected to time-lapse imaging (15-min intervals) using a Leica DMI6000 inverted 2-photon 
microscope using a Leica HC CS PL APO 10x 0.4 objective. For dark-field time-lapse imaging 
(15-min intervals), slices (not subjected to DRAQ5 labeling) were imaged using a Zeiss 
Axiovert 200M inverted microscope using a Zeiss Plan-Neofluar 5x 0.15 Ph1 objective. For 
both types of live imaging, slice cultures were maintained at 37°C in the presence of humidified 
40% O2 / 5% CO2 /55% N2, as above. Imaging was started 2-4 h after the embedding of slice 
cultures. 
 
Long et al,   30 May 2018 
 
 43 
ECM component selection 
The three ECM components HAPLN1, lumican and collagen I were identified by screening 
of several existing transcriptome datasets. ECM components were identified form the core 
matrisome published by the matrisome project (Naba et al., 2012), resulting in a total of 288 
genes. In the datasets (Fietz et al., 2012; Florio et al., 2015), we screened for ECM 
components whose mRNAs were more highly expressed in human neocortical progenitor cell 
types or germinal zones in comparison to mouse, resulting in a total of 196 genes. Once this 
list of ECM components was generated, it was compared to another dataset from E9.5 mouse 
neuroepithelium (Albert et al., 2017), from which we generated a list of ECM components 
that were expressed at this early stage, but the expression of which was decreased or lost at 
E14.5 in mouse neocortex (Fietz et al., 2012; Florio et al., 2015), resulting in 58 genes. This 
was done to identify ECM components that were expressed in human neocortex and 
specifically down-regulated in the mouse developing neocortex, as these were candidates 
likely to have an evolutionary role in neocortex development. Of these 58 genes, were 
excluded those with a FPKM value of less than 2, to identify ECM components with a mid-
high level of expression. This resulted in 28 genes. From these 28, we next selected genes 
with a FPKM value of less than 1 in mouse NPCs, to identify ECM components with lowest 
expression in the mouse at the peak of neurogenesis. This resulted in a total of 9 genes (Table 
S1). Finally, we selected those genes with the highest expression in the human, with a FPKM 
value over 4. This comparison identified the 3 ECM components selected: HAPLN1, lumican 
and collagen I (from the subunit Col1a2). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
All image analyses and quantifications were conducted using Fiji, and all statistical analyses 
were conducted using GraphPad Prism. All datasets were tested for Gaussian distribution 
(Kolmogorov-Smirnov test) prior to the selection of the appropriate statistical test; Students’ 
t-test, one-way ANOVA or two-way ANOVA (details of statistics used can be found in the 
figure legends). All datasets were analyzed blind. 
 
For quantification of IF, Fiji was used to measure the pixel density of HA, pERK1/2, 
p90RSK and His-tag staining. Measurements were taken within a defined region of interest 
(ROI) (100 µm x100 µm) in the VZ and CP (HA), or just within the CP (pERK1/2 and 
p90RSK), or within the VZ, SVZ, IZ and CP (His-tag) of each cryosection. For one human 
fetal or ferret embryonic sample, a minimum of 3 ROIs were measured per zone within a 
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single cryosection, and a minimum of 3 cryosections were analyzed per sample, followed by 
calculation of the average pixel density in each zone and sample.  
To allow the quantification of HA levels across human fetal samples of different 
developmental stages, different handling (Dresden vs. HDBR), and given that the exact 
location of tissue pieces within the neocortex was unknown, the HA IF in the CP was 
expressed relative to that in the VZ in each sample. For pERK1/2 and p90RSK IF, the 
averaged pixel density was compared to control values for each experiment, and therefore the 
data are presented relative to control (control values were set to 1.0). For HA and pERK 
quantifications, 5 individual human fetal samples were used of ages ranging from 11-14 GW, 
for p90RSK 3 individual human fetal samples were used of ages ranging from 13-14 GW. 
For His-tag quantification, the averaged pixel density in control was taken as background. 
This value was then subtracted from the pixel density measurements for HLC-/HAPLN1 
alone-/lumican alone-treated tissue. 
Nuclear distance measurements were taken in a defined ROI (30 µm x 40 µm). From each 
cryosection, 3-6 ROIs were measured within the CP and (if applicable) in the gyrus and 
sulcus. For each ROI, 4 optical sections within a 3-µm z-depth range, compressed into a 
single image, were used for measurements. To measure the distance between nuclei, 10-15 
nuclei per ROI were randomly selected. The distances between the outer surface of the 
nucleus to all neighboring nuclei were then measured. For each condition, 300-400 distances 
were measured in 3 individual fetuses. 
Quantification of the gyrification index was determined in a similar manner to in vivo 
measurements (Zilles et al., 1988) (see images below).  
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DATA AND SOFTWARE AVAILABILITY  
RNA-seq raw data have been deposited with the Gene Expression Omnibus under accession 
codes GSE106640.  
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Abbreviations 
AFM  Atomic force microscopy 
ChondABC Chondroitinase ABC 
CP  Cortical plate 
DS  Down syndrome 
E  Embryonic day 
ECM  Extracellular Matrix 
Exp.  Experiment 
FFTC  Free floating tissue culture 
GI  Gyrification index 
GW  Gestation week 
h  hours 
HA  Hyaluronic acid 
HAS  Hyaluronic acid synthase 
HLC  HAPLN1, lumican and collagen I 
HuNcx  Human neocortex 
Hyal  Hyaluronidase 
Ind. exp. Independent experiment 
NDDs  Neurodevelopmental disorders 
NPC  Neural progenitor cell 
P  Postnatal day 
PME  Prenatal methamphetamine exposure  
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Supplemental Materials 
Fig S1 – S8 
Movies S1 - S3 
Tables S1 - 2 
 
Movie legends 
 
Movie S1. Human neocortex organotypic slice culture, control, imaged for 24 h. Related 
to Figure 2. 
Organotypic slice culture of 12 GW human neocortex. Tissue has been stained with far red 
nuclei dye, DRAQ5, and embedded in PEG hydrogel. Images were taken every 15 min for 24 
h. The CP (top of the image) remains unfolded throughout imaging. Time lapse imaging was 
performed using a 2-photon confocal and 10x magnification. 
 
Movie S2. Human neocortex organotypic slice culture, with HLC-treatment, imaged for 
24 h. Related to Figure 2. 
Organotypic slice culture of 12 GW human neocortex. Tissue has been stained with far red 
nuclei dye, DRAQ5, and embedded in PEG hydrogel. Images were taken every 15 min for 24 
h. The CP starts to fold after 6 h, continues folding for the next 12 h before becoming stable 
for the last few hours of imaging. Time lapse imaging was performed using a 2-photon 
confocal and 10x magnification. 
 
Movie S3. Human neocortex organotypic slice culture, HLC-treated with the addition of 
hyaluronidases after 24 h, imaged for 72 h. Related to Figure 4. 
Organotypic slice culture of 13 GW human neocortex. Tissue was imaged on a wide-field 
system, using dark-field imaging, so did not require staining. Images were taken every 15 
min for 72 h. Imaging started 4 h after the addition of HLC, folding is already starting to 
occur. The CP continues to fold for the next 20 h. Hyaluronidases were then added to the 
slice culture (when indicated by label). The CP then unfolds, returning to the original 
smoothness and size over the next 48 h. Time-lapse imaging was performed using a wide-
field system and 5x magnification. 
 
Supplemental Excel table S1. 
Table S1. Gene enrichment lists form RNAseq. Related to Figure S6D and Figure 4. 






  
Supplemental figures  
  
Supplemental Figure 1. HAPLN1, lumican and col1a2 mRNA expression in embryonic 
mouse and fetal huNcx, secondary antibody control for IF of HAPLN1, lumican and 
collagen I, and His-tag IF of recombinant proteins in huNcx. Related to Figures 1-2. 
mRNA expression data are taken from Florio et al, 2015 (16) (A) and Fietz et al, 2012 (21) (B) 
transcriptome datasets. Col1a2 is a subunit of collagen I. (A) FPKM values for cell populations 
isolated from embryonic mouse (m) and fetal human (h) neocortex. aRG, apical radial glia; bRG, 
basal radial glia; bIP, basal intermediate progenitor-enriched fraction; N, neuron fraction (note 
that the human neuron fraction contains not only neurons but also basal radial glia in G1 (16), 
which likely account for the low levels of HAPLN1, lumican and Col1a2 mRNA expression 
observed in this fraction). (B) FPKM values for specific zones of embryonic mouse (m) and fetal 
human (h) neocortex. The FPKM values for Col1a2 are shown on the left y-axis, the HAPLN1 
and lumican FPKM values are shown on the right y-axis, as indicated by the break in the x-axis. 
VZ, ventricular zone; SVZ, subventriuclar zone; CP, cortical plate; ISVZ, inner SVZ; OSVZ, 
outer SVZ. (A, B) Error bars, SD. 
(C, D) DAPI staining (blue) and rabbit-647 secondary antibody IF (grey) of 13 GW (a) and 18 
GW (b) huNcx. This rabbit-647 secondary antibody is a control for all HAPLN1, lumican and 
collagen I IF (Figure 3), as all primary antibodies were raised in rabbit.  
(E) DAPI staining (blue) and His-tag IF (green, used to detect the His-tagged recombinant 
HAPLN1 and lumican added) of 13 GW huNcx in FFTC subjected to control, HLC-treatment, 
HAPLN1 alone and lumican alone for 24 h. 
(F) Quantification of His-tag pixel density measured in the VZ, SVZ, IZ and CP for the indicated 
treatments. Error bars, SEM. 
(C, D, E) Scale bars: 200 µm.  
    
  
Supplemental Figure 2. 13 GW huNcx slice cultures and analysis of the effect of other ECM 
components and time points on HLC-induced folding. Related to Figure 2. 
(A) DAPI staining (blue) and nestin IF (grey) of CP of 13 GW huNcx. Dashed boxes delineate 
panels to the right. Yellow dashed lines outline the smooth (top) and folded (bottom) CP. 
(B) Quantification of GI of 12-15 GW huNcx subjected to control and HLC-treatment in FFTC 
for 8, 16 and 24 h, *, P =0.004 (B), 24 h, *, P=0.0273 (C), 48 h, *, P=0.024 (D) and 72 h **, 
P=0.0038 (E).  
(F) Quantification of GI in 11-16 GW huNcx in FFTC subjected to the indicated conditions for 
24 h. ****, control vs. HLC-treatment P<0.0001, collagen I + HAPLN1 vs. HLC-treatment 
P<0.0001; ***, P=0.0001; **, P=0.0042, *, P=0.0137. Not shown: control vs. HAPLN1, *, 
P=0.0023; control vs. all other conditions, ns, P>0.05. 
(G) DAPI staining of 15 GW huNcx in FFTC subjected to control (left), HLC-treatment (middle) 
and HAPLN1 + lumican + collagen IV treatment (right). White dashed lines outline the unfolded 
(left and right) or folded (middle) CP surface.  
(H) Quantification of GI of collagen I-embedded 11-14 GW huNcx in organotypic slice culture 
subjected to the indicated conditions. **, P=0.0013 (control vs. HLC-treatment), P=0.0041 
(HLC-treatment vs. Laminin-211 + collagen IV). 
(I) Quantification of GI in 14-18 GW huNcx in FFTC subjected to the indicated conditions. **, 
P=0.0035 (control vs. HLC-treatment), P=0.0022 (HLC-treatment vs. HAPLN1 + lumican + 
collagen IV). 
(J) Quantification of GI in 12-15 GW huNcx in FFTC subjected to control, HLC-treatment and 
treatment with a basement membrane-derived ECM extract. ***, P=0.0002 (control vs. HLC-
treatment), P=0.0009 (HLC-treatment vs. HLC-treatment + basement membrane-derived ECM 
extract). 
Scale bars: (G) 200 µm. 
(B-F, H-J) Statistical tests; two-way ANOVA (B), Student’s t-test (C-E), one-way ANOVA (F, 
H-J). Error bars, SD; ns, P >0.05. Data points represent 3 ind. exp. (1 fetus/exp.) with 1-2 
FFTCs per condition per fetus and fetal samples in (B) are independent of fetal samples in (C-E), 
in (F, H-J) represent 3-5 ind. exp. (1 fetus/exp.) with 1-3 slice cultures or FFTCs per condition 
per fetus.  
 
Supplemental Figure 3. HLC-treatment does not induce folding of developing mouse and 
ferret neocortex and loss of HA does not perturb folding of developing ferret neocortex. 
Related to Figure 5.  
(A, C, E, G, I, K) DAPI staining of collagen I-embedded E14.5 mouse neocortex (A) and E33 
ferret neocortex (C) in organotypic slice culture subjected to control (left) and HAPLN1 plus 
lumican treatment (right) for 24 h, and of E33 ferret neocortex in FFTC subjected to control 
(left) and HLC-treatment (right) for 3 (E) and 4 days (G), and P9 (I) and P15 (K) ferret 
neocortex in FFTC for 2 days. 
(B, D, F, H, J, L) Quantification of GI of developing mouse and ferret neocortex subjected to the 
culture conditions and treatments specified in (A C, E, G, I, K), respectively. 
(M-O) E33 ferret neocortex in FFTC subjected to control and either HLC-treatment (M, N) or 
HLC-treatment with addition of HA (O), for 24 h. (M) Quantification of the CP/VZ ratio of HA 
immunoreactivity. (N) DAPI staining (blue) and HA IF (green). (O) Quantification of GI of E33 
ferret neocortex subjected to the indicated treatments for 48 h.  
(P, Q) P15 ferret neocortex in FFTC subjected to control and treatment with hyals plus HAS 
inhibitor for 48 h. (P) DAPI staining (blue). (Q) Quantification of GI. Statistical test used; 
Student’s t-test. Error bars, SD; ns, P >0.05. Data points represent 3 ind. exp. (1 P15 ferret/exp.) 
with 1-2 FFTCs per condition per ferret. Note the lack of sensitivity of the developing ferret 
neocortex folding to the reduction of HA levels. 
(R, S) AFM values of consecutive regions (indicated by small letters) of the same respective 
cryosection from 13 GW huNcx (R) and E33 ferret neocortex (three embryos from one litter) (S) 
in FFTC subjected to control (C) and HLC-treatment (HLC) for 24 h. Blue dashed lines indicate 
the average of the control values of the respective cryosection, grey dashed lines separate the 
control and HLC values. 
(A C, E, G, I, K, N, P) Scale bars: 200 µm. 
(B, D, F, H, J, L, M, O, Q) Statistical test used; Student’s t-test. Error bars, SD; ns, P >0.05. 
Individual data points in (B, D, F, H, J, L, M, O) represent the average value from an individual 
embryo (average of 3 images per embryo), from E14.5 mouse or E33, P9 and P15 ferret, from 3 
independent litters, and in (Q) 3 ind. exp. (1 P15 kit/exp.) with 1-2 FFTCs per condition per kit. 
 
Supplemental Figure 4. HAPLN1, lumican, collagen I, CD168 and HA IF in developing 
ferret neocortex. Related to Figure 3. 
(A-C) DAPI staining (blue) and either HAPLN1, lumican, collagen 1 IF (grey, as indicated) of 
E36 (A), P9 (B) and P15 (C) developing ferret neocortex. Dashed boxes in (B) delineate the P9 
CP and IZ areas shown in (top and bottom row, respectively), and in (C) the P15 CP gyrus and 
sulcus areas shown in (left and right panels, respectively). 
(D, E) DAPI staining (blue) and double IF for CD168 (grey) and HA (green) of P9 (D) and P15 
(E) developing ferret neocortex. Dashed boxes in (D) delineate the P9 CP and IZ areas shown in 
(top and bottom row, respectively), and in (E) the P15 CP gyrus and sulcus areas shown in (top 
and bottom row, respectively). 
Scale bars: (A-D) 200 µm and (E) 500 µm.  
  
 
 
  
Supplemental Figure 5. HLC-treatment does not cause an overt increase in cycling cortical 
progenitor cells, and cell proliferation is not essential for the HLC-induced GI increase. 
Related to Figure 6. 
(A) DAPI staining (blue), and PCNA IF (green) of 13 GW huNcx in FFTC subjected to control 
(left 2 panels) and HLC-treatment (right 2 panels).  
(B-D) Quantification of the total number of (B) PCNA-positive cells per 500 µm wide area), (C) 
pVim-positive cells per microscopic field (2000 µm wide area of tiled-images and (D) EdU-
positive cells per 500 µm wide area, EdU was given 1 hour prior to fixation, in 11-14 GW huNcx 
in FFTCs subjected to control and HLC-treatment for 24 h.  
(E) Quantification of GI of 11-14 GW huNcx in FFTC subjected to control, HLC-treatment and 
HLC-treatment with the addition of the inhibitor of proliferation, mitomycin C (10 µg/ml), for 24 
h. *, P=0.0489; ***, P=0.0009. 
(F) DAPI staining (blue, top row), and IF for the mitotic marker phospho-vimentin (pVim, green, 
bottom row) of 13 GW huNcx in FFTC subjected to control (left) and HLC-treatment (3 
examples are shown, 3 right panels) for 24 h. Dashed boxes delineate the areas of pVim IF in 
(A’).  
Note that the cell cycle length of human neocortical progenitors is estimated to be substantially 
greater than 24 h (Hansen et al., 2010, Betizeau et al., 2013, LaMonica et al., 2013).  
(A, F, F’) Scale bars: (A, F) 200 µm and (F’) 50 µm. 
(B-E) Statistical test used; Students’ t-test (B-D), one-way ANOVA (E). Error bars, SD; ns, P 
>0.05. Data points represent 3 ind. exp. (1 fetus/exp.) with 1-3 FFTCs per condition per fetus. 
 
  
 
Supplemental Figure 6. RNA sequencing of HLC-treated and control CP and qPCR 
analysis of HAS1-3 and HYAL1-4 in huNcx in FFTC for 6 and 8 h. Related to Figure 4. 
Laser capture microdissection (LCM) was used to isolate the CP from 12-14 GW huNcx in 
control and HLC-treatment (HLC) for 16 h of FFTC (when folding has just started). When HLC-
treated CP was compared to control CP using the standard cut-off levels of significance (P 
<0.01), zero differentially expressed genes were identified. When this cut-off level was raised to 
P <0.05, a total of 235 genes were found to be up-regulated after HLC-treatment and 203 were 
down-regulated, as shown in the volcano plot (A) of differentially expressed genes (P <0.05). 
True and False indicate if the differential expression of the gene is statistically significant. (B) 
MA plot of differentially expressed genes (p<0.05) of HLC-treatment CP compared to control. 
True and False indicate if the differential expression of the gene is statistically significant, NA 
indicates not applicable.  
(C) Principle component analysis (PCA) plot of the 3 HLC-treated samples (red) and control 
(blue) samples.  
(D) Fold enrichment of GO biological process terms from RNAseq analysis. Terms listed all 
show a fold enrichment greater than 2 and have a P <0.05. The genes included within these terms 
are outlined in table S2. 
(E) qPCR analysis of mRNA levels of HAS1-3 and HYAL1-4 in 13-16 GW huNcx in FFTC 
subjected to control and HLC-treatment for 6 and 8 h. Data is represented as fold change in 
HLC-treatment compared to control. Three independent qPCR experiments were performed (1 
fetus/exp.). Error bars, SEM. 
  
 
Supplemental Figure 7. 24-hour HLC-treatment and degradation of HA in 22 GW huNcx, 
analysis of HA levels after HLC-treatment + hyals or chondABC in 12-14 GW huNcx, 
analysis of the distance between nuclei in the CP of 11-14 GW huNcx in FFTC and of non-
cultured 22 GW huNcx, and analysis of p90RSK. Related to Figures 4-6. 
(A) DAPI staining (blue) and IF for HA (red) in 14 GW huNcx in FFTC subjected to control 
(far- left), HLC-treatment (centre left), HLC-treatment + hyalruonidases @ 24 h (centre right) 
and HLC-treatment + chondABC (far right) for 24 h (except for the condition HLC-treatment + 
hyaluronidases @ 24 h (HLC-treatment for 48 h with addition of hyals at 24 h)). 
(B) Quantification of the CP/VZ ratio of HA immunoreactivity in 12-14 GW huNcx in FFTC 
subjected to control and HLC-treatment + chondABC for 24 h. *, P=0.0201. 
(C) DAPI staining (blue) and IF for HA (red) in the CP of 22 GW huNcx in FFTC subjected to 
control (left) and treatment with HAS inhibitor (right) for 4 days. 
(D) Quantification of GI in 22 GW huNcx in FFTC subjected to the indicated treatments for 24 
h. *, P=0.0379. 
(E) Quantification of gyrus CP thickness (filled triangles, left y-axis) and intergyral distance 
(open circles, right y-axis) relative to sulcus CP thickness, in 11-16 GW neocortex in FFTC for 
24 h subjected to HLC-treatment and 22 GW neocortex in FFTC for subjected to HLC-treatment 
or control for 4 days. Blue dashed line delineates sulcus CP thickness, set to 1.0. 
(F) Quantification of the CP/VZ ratio of HA immunoreactivity in 22 GW huNcx in FFTC 
subjected to control and treatment with HAS inhibitor for 4 days. **, P=0.0087. 
(G) Quantification of GI of 22 GW huNcx in FFTC subjected to the indicated treatments for 24 
h. *, P=0.0247 (control vs. hyals), P=0.0394 (control vs. HAS inhibitor). 
(H-M) Quantification of the average distance between nuclei (H, J, L) in the gyri vs. sulci in the 
CP of non-cultured 22 GW neocortex **, P=0.0068 (H, I), in the CP of 11-14 GW neocortex in 
FFTC subjected to control and HLC-treatment for 8 h (J, K) and 16 h (L, M, separate analysis of 
HLC-induced gyri vs. sulci) was determined, *, P=0.0452. (I, K, M) Frequency distribution 
histograms for the distance between nuclei. Note the shift to the right upon HLC-treatment 
already after 8 h (I), and in HLC-induced (K) and physiologically formed (M) gyri vs. sulci. 
(N) Quantification of p90RSK immunoreactivity in the CP of 13-16 GW huNcx in FFTC 
subjected to the indicated treatments for 24 h, relative to control indicated by the blue dashed 
line (set to 1.0). *, P=0.363. 
(O) DAPI staining (blue) and p90RSK IF (grey) in the CP of 14 GW huNcx in FFTC subjected 
to control (top), HLC-treatment (middle) and HLC-treatment + ERK inhibitor (bottom) for 24 h. 
(E, F, O) Scale bars: (E, F) 200 µm and (O) 50 µm. 
(A-E, F-K) Statistical tests used; one-way ANOVA (A, E, J), Student’s t-test (B, D, F, H). Error 
bars, SD; ns, P >0.05. (A-E) Data points represent 3 ind. exp. (1 fetus/exp.) with 1-2 FFTCs per 
condition per fetus. (F, H, J) Data are presented as whisker plots showing the minimum, mean 
and maximum values. Error bars, SEM; ns, P >0.05; *, P <0.05; **, P <0.01. (F-K) The data in 
each graph represent 3 ind. exp. (1 fetus/exp.) with 1-2 FFTCs per condition. 
  
 
Supplemental Figure 8. AFM measurements of HLC-induced ECM stiffness changes at the 
onset of HLC-induced folding in 12-14 GW huNcx and in 13-15 GW huNcx after various 
treatments at 24 h in FFTC. Related to Figure 5. 
(A) Schematic of the steps performed to prepare human fetal (and embryonic ferret) neocortex 
for AFM measurements; (i) FFTC followed by preparation of tissue slices; (ii) freeze-thawing of 
tissue slices; (iii) cryosectioning of tissue slices followed by thawing and drying; (iv) AFM 
measurements of CP ECM stiffness on these cryosections. VS, ventricular surface.  
(B) Bright-field image of a cryosection of 13 GW huNcx after HLC-treatment in FFTC for 24 h, 
prepared for AFM measurement. Red boxes delineate the areas measured; within each box 9 
measurements were taken. Numbers indicate the average Young’s modulus value for each box 
measured. 
(C, D) AFM measurements in the CP of 12 (top rows), 13 (middle rows) and 14 (bottom rows) 
GW huNcx in FFTC subjected to either control (blue) or HLC-treatment (green) for 8 h (C) and 
16 h (D), plotted against the distance measured along the length of the CP from the first point 
measured (0) (in µm). Each graph represents one FFTC from one fetus. 
(E) AFM measurements in the CP of 13 (left column), 14 (middle column) and 15 (right column) 
GW huNcx in FFTC subjected to either control (dark blue), HLC-treatment (green), HLC-
treatment + CD168 antibody (red), HLC-treatment + ERK inhibitor (orange), HLC + chondABC 
(purple) and HLC-treatment + hyals (light blue) for 24 h, plotted against the distance measured 
along the length of the CP from the first point measured (0) (in µm). Each graph represents one 
FFTC from one fetus. 
  
 
Supplemental Figure 9. Method of GI measurement. Related to Figure 2. 
(A) DAPI staining (blue) and nestin immunofluorescence (grey) of 13 GW huNcx after HLC-
treatment. Image on the right shows how GI was measured: the inner, folded outline of the basal 
side of the CP (dashed green line) is divided by the hypothetical, smooth outline of the basal side 
of the CP (dashed red line).  
  
Table S2. List of primers used for mRNA level analysis by qPCR. Related to STAR 
methods. 
Gene symbol forward primer reverse primer 
HAS1 GTAGCCTTCAATGTGGAGCG CAGGCCTCAAGAAACTGCTG 
HAS2 GGACGACTTTATGACCAAGAGC GCAGCTGTGATTCCAAGGAG 
HAS3 GCGATTCGGTGGACTACATC TCCAGGACTCGAAGCATCTC 
HYAL1 TCTGGGTGAGCTGGGAAAAT GAAGGGCCCCAGTGTAGTG 
HYAL2 GTCTTCACACGACCCACCTA GCACTCTCGCCAATGGTAGA 
HYAL3 CCTATGTCCGCCTCACACA CTGCACTCACACCAATGGAC 
HYAL4 GCAGGCATTGTTATTTGGGGA AGCTCTGGTCACATTGGCTA 
HPRT1 GCTGAGGATTTGGAAAGGGTG GCTACAATGTGATGGCCTCC 
 
 
 
